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Unchanged

Summary of findings {#CD012776-sec1-0001}
===================

###### 

'Summary of findings\' table 1

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- -------------------------------------- ---------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pyrethroid‐piperonyl butoxide (PBO) nets compared to long‐lasting insecticidal nets (LLIN) for malaria control where insecticide resistance is high**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Patient or population:***Anopheles gambiae* complex or *Anopheles funestus* group  **Setting:** areas of high insecticide resistance  **Intervention:** pyrethroid‐PBO nets  **Comparison:** LLIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Anticipated absolute effects^\*^ (95% CI)**   **Relative effect  (95% CI)**   **Number of participants  (trials)**   **Certainty of the evidence  (GRADE)**         **Comments**                             

  **Risk with LLIN**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **Risk with pyrethroid‐PBO nets**                                                                                                                                                                              

  **Prevalence of malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  527 per 1000^a^                                 211 per 1000 (105 to 422)^a^    OR 0.40 (0.20 to 0.80)                 3966 people (1 trial, 1 comparison)            ⊕⊕⊕⊝  MODERATE^b,c^\                     Prevalence of malaria is probably decreased with pyrethroid‐PBO nets compared to standard LLINs in areas of high insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   *due to indirectness*                    

  **Mosquito mortality (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     238 per 1000^a^                                 438 per 1000  (381 to 503)^a^   RR 1.84  (1.60 to 2.11)                14,620 mosquitoes  (5 trials, 9 comparisons)   ⊕⊕⊕⊕  HIGH^b^                            Mosquito mortality is increased with unwashed pyrethroid‐PBO nets compared to standard unwashed LLINs in areas of high insecticide resistance.

  **Mosquito mortality (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       201 per 1000^a^                                 242 per 1000  (177 to 328)^a^   RR 1.20  (0.88 to 1.63)                10,268 mosquitoes  (4 trials, 5 comparisons)   ⊕⊝⊝⊝  VERY LOW^d,e^\                     We do not know if pyrethroid‐PBO nets have an effect on mosquito mortality in areas of high insecticide resistance when the nets have been washed.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   *due to imprecision and inconsistency*   

  **Blood‐feeding success (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  438 per 1000^a^                                 263 per 1000  (241 to 311)^a^   RR 0.60\                               14,000 mosquitoes  (4 trials, 8 comparisons)   ⊕⊕⊕⊕  HIGH^b^                            Mosquito blood‐feeding success is decreased with unwashed pyrethroid‐PBO nets compared to standard unwashed LLINs in areas of high insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (0.50 to 0.71)                                                                                                                 

  **Blood‐feeding success (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    494 per 1000^a^                                 400 per 1000  (356 to 454)^a^   RR 0.81  (0.72 to 0.92)                9674 mosquitoes  (3 trials, 4 comparisons)     ⊕⊕⊕⊕  HIGH^b^                            Mosquito blood‐feeding success is decreased with washed pyrethroid‐PBO nets compared to standard washed LLINs in areas of high insecticide resistance.

  \***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **Abbreviations: CI:** confidence interval; **LLIN:** long‐lasting insecticidal nets; **OR:** odds ratio; **PBO:** pyrethroid‐piperonyl butoxide; **RR:** risk ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **GRADE Working Group grades of evidence**  **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.  **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.  **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.                                                                                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- -------------------------------------- ---------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Original numbers used in this table, however in pooled analysis events and total numbers were generated from cluster‐adjusted results which uses the effective sample size. Note that cluster adjustments do not change the point estimate of the effect size, just the standard error.  ^b^Not downgraded for imprecision: both best and worst case scenarios in this situation are important effects.  ^c^Downgraded by one for indirectness: the outcome is highly context specific and there is only one trial included here.  ^d^Downgraded by two for inconsistency due to unexplained qualitative heterogeneity.  ^e^Downgraded by one for imprecision due to wide CIs.

###### 

'Summary of findings\' table 2

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------------------------- ---------------------------------------- --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pyrethroid‐piperonyl butoxide (PBO) nets compared to long‐lasting insecticidal nets (LLIN) for malaria control where insecticide resistance is moderate**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Patient or population:***Anopheles gambiae* complex or *Anopheles funestus* group  **Setting:** areas of moderate insecticide resistance  **Intervention:** pyrethroid‐PBO nets  **Comparison:** LLIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Anticipated absolute effects^\*^ (95% CI)**   **Relative effect  (95% CI)**   **Number of mosquitoes  (experimental hut trials)**   **Certainty of the evidence  (GRADE)**   **Comments**                            

  **Risk with LLIN**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **Risk with pyrethroid‐PBO nets**                                                                                                                                                                                      

  **Mosquito mortality (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     439 per 1000^a^                                 509 per 1000  (386 to 675)^a^   RR 1.16  (0.88 to 1.54)                               242  (1 trial, 1 comparison)             ⊕⊕⊝⊝  LOW^b,c,d^\                       There may be little or no difference in the effect of unwashed pyrethroid‐PBO nets on mosquito mortality compared to standard unwashed LLINs in areas of moderate insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision and indirectness*   

  **Mosquito mortality (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       287 per 1000^a^                                 307 per 1000  (213 to 443)^a^   RR 1.07  (0.74 to 1.54)                               329  (1 trial, 1 comparison)             ⊕⊕⊝⊝  LOW^b,c,d^\                       There may be little or no difference in the effect of washed pyrethroid‐PBO nets on mosquito mortality compared to standard washed LLINs (washed) in areas of moderate insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision and indirectness*   

  **Blood‐feeding success (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  553 per 1000^a^                                 481 per 1000  (370 to 624)^a^   RR 0.87  (0.67 to 1.13)                               242  (1 trial, 1 comparison)             ⊕⊕⊝⊝  LOW^b,c,d^\                       There may be little or no difference in the effect of pyrethroid‐PBO nets (unwashed) on mosquito blood‐feeding success compared to standard LLINs in areas of moderate insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision and indirectness*   

  **Blood‐feeding success (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    586 per 1000^a^                                 533 per 1000  (434 to 662)^a^   RR 0.91  (0.74 to 1.13)                               329  (1 trial, 1 comparison)             ⊕⊕⊝⊝  LOW^b,c,d^\                       There may be little or no difference in the effect of washed pyrethroid‐PBO nets on mosquito blood‐feeding success compared to standard washed LLINs in areas of moderate insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision and indirectness*   

  \***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **Abbreviations: CI:** confidence interval; **LLIN:** long‐lasting insecticidal nets; **PBO:** pyrethroid‐piperonyl butoxide; **RR:** risk ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  **GRADE Working Group grades of evidence**  **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.  **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.  **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.                                                                                                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------------------------- ---------------------------------------- --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Original numbers used in this table, however in pooled analysis, we generated events and total numbers from cluster‐adjusted results, which used the effective sample size. Note that cluster adjustments do not change the point estimate of the effect size, just the standard error.  ^b^Not downgraded for inconsistency as only one trial measured this outcome in this setting.  ^c^Downgraded by one for imprecision due to wide CIs.  ^d^Downgraded by one for indirectness: the outcome is highly context‐specific and there is only one trial included here.

###### 

'Summary of findings\' table 3

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------- ----------------------------------------------------- ---------------------------------------- ---------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pyrethroid‐piperonyl butoxide (PBO) nets compared to long‐lasting insecticidal nets (LLIN) for malaria control where insecticide resistance is low**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Patient or population:***Anopheles gambiae* complex or *Anopheles funestus* group  **Setting:** areas of low insecticide resistance  **Intervention:** pyrethroid‐PBO nets  **Comparison:** LLIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Anticipated absolute effects^\*^ (95% CI)**   **Relative effect  (95% CI)**    **Number of mosquitoes  (experimental hut trials)**   **Certainty of the evidence  (GRADE)**   **Comments**                             

  **Risk with LLIN**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **Risk with pyrethroid‐PBO nets**                                                                                                                                                                                        

  **Mosquito mortality (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     871 per 1000^a^                                 958 per 1000  (914 to 1000)^a^   RR 1.10  (1.05 to 1.16)                               708  (1 trial, 2 comparisons)            ⊕⊕⊕⊝  MODERATE^b^\                       There is probably little or no difference in the effect of unwashed pyrethroid‐PBO nets on mosquito mortality compared to standard unwashed LLINs in areas of low insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             *due to imprecision*                     

  **Mosquito mortality (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       620 per 1000^a^                                 719 per 1000  (514 to 1000)^a^   RR 1.16  (0.83 to 1.63)                               878  (1 trial, 2 comparisons)            ⊕⊝⊝⊝  VERY LOW^c,d^\                     We do not know if pyrethroid‐PBO nets have an effect on mosquito mortality in areas of low insecticide resistance when the nets have been washed.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             *due to imprecision and inconsistency*   

  **Blood‐feeding success (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  72 per 1000^a^                                  48 per 1000  (4 to 529)^a^       RR 0.67  (0.06 to 7.37)                               708  (1 trial, 2 comparisons)            ⊕⊝⊝⊝  VERY LOW^c,d^\                     We do not know if unwashed pyrethroid‐PBO nets have an effect on mosquito blood‐feeding success in areas of low insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             *due to imprecision and inconsistency*   

  **Blood‐feeding success (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    149 per 1000^a^                                 223 per 1000  (132 to 377)^a^    RR 1.50  (0.89 to 2.54)                               878  (1 trial, 2 comparisons)            ⊕⊕⊝⊝  LOW^d^\                            Mosquito blood‐feeding success may decrease with washed pyrethroid‐PBO nets compared to standard washed LLINs in areas of low insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             *due to inconsistency*                   

  \***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **Abbreviations: CI:** confidence interval; **LLIN:** long‐lasting insecticidal nets; **PBO:** pyrethroid‐piperonyl butoxide; **RR:** risk ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **GRADE Working Group grades of evidence**  **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.  **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.  **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.                                                                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------- ----------------------------------------------------- ---------------------------------------- ---------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Original numbers used in this table, however in pooled analysis events and total numbers were generated from cluster adjusted results which uses the effective sample size. Note that cluster adjustments do not change the point estimate of the effect size, just the standard error.  ^b^Downgraded by one for imprecision due to wide CIs.  ^c^Downgraded by one for inconsistency due to unexplained heterogeneity.  ^d^Downgraded by two for imprecision due to extremely wide CIs.

###### 

'Summary of findings\' table 4

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pyrethroid‐piperonyl butoxide (PBO) nets compared to long‐lasting insecticidal nets (LLIN) for malaria control where mosquitoes are susceptible**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  **Patient or population:***Anopheles gambiae* complex or *Anopheles funestus* group  **Setting:** areas of insecticide‐susceptible mosquitoes\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Intervention:** pyrethroid‐PBO nets  **Comparison:** LLIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Anticipated absolute effects^\*^ (95% CI)**   **Relative effect  (95% CI)**   **Number of mosquitoes  (experimental hut trials)**   **Certainty of the evidence  (GRADE)**   **Comments**                             

  **Risk with LLIN**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **Risk with pyrethroid‐PBO nets**                                                                                                                                                                                       

  **Mosquito mortality (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     392 per 1000^a^                                 471 per 1000  (251 to 887)^a^   RR 1.20  (0.64 to 2.26)                               2791  (2 trials, 2 comparisons)          ⊕⊕⊝⊝  LOW^b^\                            There may be little or no difference in the effect of unwashed pyrethroid‐PBO nets on mosquito mortality compared to standard unwashed LLINs in areas of no insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision*                     

  **Mosquito mortality (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       457 per 1000^a^                                 489 per 1000  (420 to 571)^a^   RR 1.07  (0.92 to 1.25)                               2644  (2 trials, 2 comparisons)          ⊕⊕⊝⊝  LOW^b^\                            There may be little or no difference in the effect of washed pyrethroid‐PBO nets on mosquito mortality compared to standard washed LLINs in areas of no insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision*                     

  **Blood‐feeding success (unwashed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  57 per 1000^a^                                  29 per 1000  (6 to 132)^a^      RR 0.50  (0.11 to 2.32)                               2791  (2 trials, 2 comparisons)          ⊕⊝⊝⊝  VERY LOW^b,c^\                     We do not know if unwashed pyrethroid‐PBO nets have an effect on mosquito blood‐feeding success in areas of no insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision and inconsistency*   

  **Blood‐feeding success (washed nets)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    64 per 1000^a^                                  82 per 1000  (52 to 131)^a^     RR 1.28  (0.81 to 2.04)                               2644  (2 trials, 2 comparisons)          ⊕⊕⊝⊝  LOW^b^\                            There may be little or no difference in the effect of washed pyrethroid‐PBO nets on mosquito blood‐feeding success compared to standard washed LLINs in areas of no insecticide resistance.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            *due to imprecision*                     

  \***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **Abbreviations: CI:** confidence interval; **LLIN:** long‐lasting insecticidal nets; **PBO:** pyrethroid‐piperonyl butoxide; **RR:** risk ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **GRADE Working Group grades of evidence**  **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.  **Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  **Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.  **Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.                                                                                                                                                                                                                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------- ----------------------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Original numbers used in this table, however in pooled analysis, events and total numbers were generated from cluster‐adjusted results, which use the effective sample size. Note that cluster adjustments do not change the point estimate of the effect size, just the standard error.  ^b^Downgraded by two for imprecision due to extremely wide CIs.  ^c^Downgraded by one for inconsistency due to unexplained heterogeneity.

Background {#CD012776-sec1-0002}
==========

Description of the condition {#CD012776-sec2-0001}
----------------------------

Substantial progress has been made in reducing the burden of malaria in the 21st century. It is estimated that the clinical incidence of *Plasmodium falciparum* malaria in Africa dropped by 40% between 2000 and 2015, equating to the prevention of 663 million cases ([Bhatt 2015](#CD012776-bbs2-0026){ref-type="ref-list"}; [WHO‐GMP 2015](#CD012776-bbs2-0060){ref-type="ref-list"}). However progress has stalled in recent years ([WHO 2017a](#CD012776-bbs2-0057){ref-type="ref-list"}). Targeting the mosquito vector has proven to be the most effective method of malaria prevention in Africa, with over two‐thirds of the malaria cases averted in the first 15 years of this century attributed to scale‐up in the use of long‐lasting insecticidal nets (LLINs), ([Bhatt 2015](#CD012776-bbs2-0026){ref-type="ref-list"}). This method of malaria prevention is particularly effective in Africa where the major malaria vectors, *Anopheles gambiae* and *Anopheles funestus*, are largely endophagic (feed indoors) and endophilic (rest indoors after blood feeding).

Currently only one insecticide class, the pyrethroids, is commonly used to treat LLINs; pyrethroids have the required dual properties of low mammalian toxicity and rapid insecticidal activity ([Zaim 2000](#CD012776-bbs2-0066){ref-type="ref-list"}), and their repellent or contact irritant effects may enhance the personal protection of LLINs. Unfortunately, resistance to pyrethroids is now widespread in African malaria vectors ([Ranson 2016](#CD012776-bbs2-0046){ref-type="ref-list"}). This may be the result of mutations in target‐site proteins (target‐site resistance), ([Ranson 2011](#CD012776-bbs2-0045){ref-type="ref-list"}; [Ridl 2008](#CD012776-bbs2-0048){ref-type="ref-list"}), which results in reduced sensitivity to the insecticide or increased activity of detoxification enzymes (metabolic resistance) ([Mitchell 2012](#CD012776-bbs2-0040){ref-type="ref-list"}; [Stevenson 2011](#CD012776-bbs2-0051){ref-type="ref-list"}), or other as yet poorly‐described resistance mechanisms, or a combination of all or some of these factors. The evolution of insecticide resistance and its continuing spread threatens the operational success of malaria vector control interventions. The current impact of this resistance on malaria transmission is largely unquantified and will vary depending on the level of resistance, malaria endemicity, and proportion of the human population using LLINs ([Churcher 2016](#CD012776-bbs2-0028){ref-type="ref-list"}). A recent multi‐country trial found no evidence that pyrethroid resistance reduced the personal protection provided by use of LLINs ([Kleinschmidt 2018](#CD012776-bbs2-0037){ref-type="ref-list"}). However, it is generally accepted that resistance will eventually erode the efficacy of pyrethroid‐only LLINs and that innovation in the LLIN market is essential to maintain the efficacy of this preventative measure ([MPAC 2016](#CD012776-bbs2-0041){ref-type="ref-list"}).

Description of the intervention {#CD012776-sec2-0002}
-------------------------------

One way of controlling insecticide‐resistant mosquito populations is through the use of insecticide synergists. Synergists are generally non‐toxic and act by enhancing the potency of insecticides. Piperonyl butoxide (PBO) is a synergist that inhibits specific metabolic enzymes within mosquitoes, and has been incorporated into pyrethroid‐treated LLINs to form PBO‐combination nets (hereafter referred to as pyrethroid‐PBO nets). Insecticide‐synergist combination nets represent a new product class with the capacity to affect insecticide‐resistant populations. In 2017 the World Health Organization (WHO), gave pyrethroid‐PBO nets an interim endorsement as a new vector control class and recommended that countries consider deploying these nets in areas where pyrethroid resistance has been confirmed in the main malaria vectors ([WHO‐GMP 2017a](#CD012776-bbs2-0061){ref-type="ref-list"}).

Currently there are five pyrethroid‐PBO nets in production: Olyset® Plus; PermaNet® 3.0; Veeralin® LN; and DawaPlus 3.0 and 4.0. Olyset Plus, which is manufactured by Sumitomo Chemical Company Ltd, is a polyethylene net treated with permethrin (20 g/kg ± 25%) and PBO (10 g/kg ± 25%) across the whole net ([Sumitomo 2013](#CD012776-bbs2-0053){ref-type="ref-list"}). PermaNet 3.0, which is manufactured by Vestergaard Frandsen, is a mixed polyester (sides) polyethylene (roof) net treated with deltamethrin and PBO; PBO is only found on the roof of the net (25 g/kg ± 25%) and the concentration of deltamethrin varies depending on location (roof: 4.0 g/kg ± 25%) and yarn type (sides: 75 denier (thickness) yarn with 70 cm lower border 2.8 g/kg ± 25%, 100 denier (thickness) yarn without border 2.1 g/kg ± 25%; [Vestergaard 2015](#CD012776-bbs2-0054){ref-type="ref-list"}). Veeralin LN, manufactured by Vector Control Innovations Private Ltd, is a polyethylene net treated with alpha‐cypermethrin (6.0 g/kg) and PBO (2.2 g/kg) across the whole net ([WHOPES 2016](#CD012776-bbs2-0064){ref-type="ref-list"}). DawaPlus 3.0 and 4.0 are manufactured by Tana Netting, UAE, and contain PBO on the roof only (3.0), or on all sides (4.0); deltamethrin suspension concentrate (SC) is coated on knitted multi‐filament polyester fibres, at the target dose of 1.33 g/kg in 75 denier (thickness) yarn and 1 g/kg in 100 denier (thickness) yarn, corresponding to 40 mg of deltamethrin per m^2^, using a polymer as a binder. Ownership of DawaPlus 4.0 is currently in the process of transferring ownership to NRS Moon netting FZE ([WHO 2018](#CD012776-bbs2-0059){ref-type="ref-list"}).

How the intervention might work {#CD012776-sec2-0003}
-------------------------------

PBO inhibits metabolic enzyme families, in particular the cytochrome P450 enzymes that detoxify or sequester pyrethroids. Increased production of P450s is thought to be the most potent mechanism of pyrethroid resistance in malaria vectors, and pre‐exposure to PBO has been shown to restore susceptibility to pyrethroids in laboratory bioassays on multiple pyrethroid‐resistant vector populations ([Churcher 2016](#CD012776-bbs2-0028){ref-type="ref-list"}).

Widespread use of conventional LLINs provides both personal and community protection from malaria ([Bhatt 2015](#CD012776-bbs2-0026){ref-type="ref-list"}; [Lengeler 2004](#CD012776-bbs2-0038){ref-type="ref-list"}). In areas where the mosquito populations are resistant to pyrethroids, experimental hut trials (as described in the '[Types of studies](#CD012776-sec3-0001){ref-type="sec"}\' section), have shown that mosquito mortality rates and protection from blood feeding are substantially reduced when using conventional LLINs ([Abílio 2015](#CD012776-bbs2-0023){ref-type="ref-list"}; [Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Bobanga 2013](#CD012776-bbs2-0027){ref-type="ref-list"}; [N\'Guessan 2007](#CD012776-bbs2-0042){ref-type="ref-list"}; [Riveron 2015](#CD012776-bbs2-0049){ref-type="ref-list"}; [Yewhalaw 2012](#CD012776-bbs2-0065){ref-type="ref-list"}). The addition of PBO to pyrethroids in LLINs can restore the killing effects of LLINs in areas where this has been eroded by insecticide resistance. LLINs that contain PBO have been evaluated in multiple experimental hut trials across Africa ([Adeogun 2012](#CD012776-bbs2-0024){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}). In most settings, the pyrethroid‐PBO nets resulted in higher rates of mosquito mortality and greater blood‐feeding inhibition than conventional LLINs, although the magnitude of this effect was variable. Village trials have measured the impact on sporozoite infection rates in mosquitoes with mixed results ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}). Recently, a cluster‐randomized trial in Tanzania demonstrated that use of pyrethroid‐PBO nets can reduce malaria prevalence in children ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}).

Why it is important to do this review {#CD012776-sec2-0004}
-------------------------------------

All LLINs approved by the WHO Prequalification Team (formerly the WHO Pesticide Evaluation Scheme (WHOPES)), contain pyrethroids as the sole active ingredient. Five LLINs that contain PBO have interim approval ([WHOPES 2016](#CD012776-bbs2-0064){ref-type="ref-list"}), and have been recognized as a new product class by WHO ([WHO‐GMP 2017a](#CD012776-bbs2-0061){ref-type="ref-list"}). As pyrethroid‐PBO nets are generally more expensive than conventional LLINs, it is important to determine if they are superior to conventional LLINs and, if so, under what circumstances, to enable cost‐effectiveness trials to be performed to inform procurement decisions.

An Expert Review Group (ERG) commissioned by the WHO has recommended pyrethroid‐PBO nets be considered for use in areas where the major malaria vectors are resistant to pyrethroids ([WHO‐GMP 2017a](#CD012776-bbs2-0061){ref-type="ref-list"}). This recommendation was largely based on a single randomized controlled trial of one pyrethroid‐PBO net type conducted in Tanzania ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}), but also supported by a meta‐analysis of performance of pyrethroid‐PBO nets in experimental hut trials, which was used to parameterize a malaria transmission model to predict the public health benefit of pyrethroid‐PBO nets ([Churcher 2016](#CD012776-bbs2-0028){ref-type="ref-list"}). However confusion remains over the settings in which pyrethroid‐PBO nets should be deployed. The WHO recommendation is that countries should consider deployment of this new product class in areas with intermediate levels of pyrethroid resistance but calls for further evidence, including data from a second clinical trial. This guidance has been adopted by some net providers; for example, the President\'s Malaria Initiative (PMI) ([PMI 2018](#CD012776-bbs2-0044){ref-type="ref-list"}).

In an attempt to assess the evidence of the effectiveness of pyrethroid‐PBO nets against African malaria vectors in areas with differing levels of insecticide resistance, we have conducted a systematic review of all relevant trials and examined both epidemiological and entomological endpoints. We appreciate that the evaluation of PBO will depend on trials where the background insecticide and dose is the same in both intervention and control groups and are aware that most trials have evaluated pyrethroid‐PBO nets against pyrethroid‐only LLINs with different background insecticides and doses, which confounds the effects.

One of the problems with this research field is that pyrethroid‐PBO nets are commercial products. The pyrethroid‐PBO nets currently undergoing clinical trials have had additional alterations made to them, such as changing the concentration or rate at which the pyrethroid is released. However, these are the products for which policy decisions are needed, based on evidence related to their relative effectiveness. Thus, in this Cochrane Review, we sought direct evidence for PBO alone on the effectiveness of nets, and examined the evidence concerning the effectiveness of commercial products. During these comparisons, we considered other potential confounding factors.

Objectives {#CD012776-sec1-0003}
==========

Evaluate whether adding PBO to pyrethroid LLINs increases the epidemiological and entomological effectiveness of the nets.Compare the effects of pyrethroid‐PBO nets currently in commercial development or on the market with their non‐PBO equivalent in relation to:malaria infection (prevalence or incidence);entomological outcomes.

Methods {#CD012776-sec1-0004}
=======

Criteria for considering studies for this review {#CD012776-sec2-0005}
------------------------------------------------

### Types of studies {#CD012776-sec3-0001}

#### Objective 1 {#CD012776-sec4-0001}

We included:

laboratory bioassay trials (for example, cone bioassays, tunnel tests);experimental hut trials; andvillage trials.

#### Objective 2 (a and b) {#CD012776-sec4-0002}

We included:

experimental hut trials;village trials; andclinical trials.

See [Table 8](#CD012776-tbl-0008){ref-type="table"} for WHOPES definitions in detail.

###### 

World Health Organization Pesticide Evaluation Scheme (WHOPES) classification

  ------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **WHOPES Phase**                           **Definition**

  WHOPES Phase I. Laboratory bioassays       Cone bioassays: these are studies that are conducted in the laboratory setting and use standard WHO protocols ([WHO 2013](#CD012776-bbs2-0055){ref-type="ref-list"}, Section 2.2.1), where mosquitoes are exposed to a suitable LLIN (treated intervention or untreated control), for three minutes using a standard plastic WHO cone. Following net exposure, mosquitoes are transferred to a holding container and maintained on a sugar solution diet while entomological outcomes (mosquitoes knocked down one hour post‐exposure, and mosquito mortality 24 hours post‐exposure), are measured.\
                                             Tunnel tests: these are studies conducted in the laboratory setting that use standard WHO protocols ([WHO 2013](#CD012776-bbs2-0055){ref-type="ref-list"}, Section 2.2.2). Mosquitoes are released into a glass tunnel covered at each end with untreated netting. The intervention or control LLIN net sample is placed one‐third down the length of the tunnel and the net contains nine holes that enable mosquitoes to pass through. A suitable bait is immobilized in the shorter section of the tunnel where it is available for mosquito biting. Mosquitoes are released into the opposite end of the tunnel and must make contact with the net and locate holes before being able to feed on the bait. After 12 to 15 hours, mosquitoes are removed from both sections of the tunnel and entomological outcomes (the number of mosquitoes in each section, mortality, and blood‐feeding inhibition at the end of the assay and 24 hours post‐exposure), are recorded.\
                                             Wire‐ball bioassays: these are studies conducted in the laboratory setting where mosquitoes are introduced into a wire‐ball frame that has been covered with either the intervention or control LLIN. Mosquitoes are exposed for three minutes, after which they are transferred to a holding container and entomological outcomes (mosquitoes knocked down one hour post‐exposure, and mosquito mortality 24 hours post‐exposure), are measured.

  WHOPES Phase II. Experimental hut trials   WHOPES Phase II experimental hut trials are field trials conducted in Africa where wild mosquito populations or local colonized populations are evaluated. Volunteers or livestock sleep in experimental huts under a purposefully holed LLIN, with one person or animal per hut. Huts are designed to resemble local housing based on a West or East African design ([WHO 2013](#CD012776-bbs2-0055){ref-type="ref-list"}; Section 3.3.1‐2). However they have identical design features, such as eave gaps or entry slits to allow mosquitoes to enter, and exit traps to capture exiting mosquitoes. LLINs and volunteers are randomly allocated to huts and rotated in a Latin square to avoid bias, with huts cleaned between rotations to avoid contamination. Several nets, including an untreated control net, can be tested at the same time. Dead and live mosquitoes are collected each morning from inside the net, inside the hut, and inside the exit traps. They are then scored as either blood‐fed or non‐blood‐fed, and either alive or dead, and live mosquitoes are maintained for a further 24 hours to assess delayed mosquito mortality.

  WHOPES Phase III. Village trials           WHOPES Phase III village trials are village trials conducted in Africa where wild mosquito populations are evaluated. Villages chosen to be included in the study are similar in terms of size, housing structure, location, and the data available on the insecticide resistance status of the local malaria vectors. Households are assigned either conventional LLINs or PBO‐LLINs. Randomization can be at the household or village level. Adult mosquitoes are collected from the study houses and mosquito density is measured. An indication of malaria transmission is measured in the study sites either by recording infections in mosquitoes, malaria prevalence, or malaria incidence.
  ------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: LLIN: long‐lasting insecticidal nets; PBO: pyrethroid‐piperonyl butoxide; WHOPES: World Health Organization Pesticide Evaluation Scheme

### Types of participants {#CD012776-sec3-0002}

#### Mosquitoes {#CD012776-sec4-0003}

*Anopheles gambiae* complex or *Anopheles funestus* group. Included trials had to test a minimum of 50 mosquitoes per trial arm. We included all mosquito populations and examined the insecticide resistance level (measured using phenotypic resistance) during data analysis.

#### Humans {#CD012776-sec4-0004}

Adults and children living in malaria‐endemic areas.

### Types of interventions {#CD012776-sec3-0003}

#### Intervention {#CD012776-sec4-0005}

Combination LLIN treated with both PBO and a pyrethroid insecticide. The LLINs must have received a minimum of interim‐WHO approval ([Table 9](#CD012776-tbl-0009){ref-type="table"}), and LLINs had to be treated with a WHO‐recommended dose of pyrethroid ([Table 10](#CD012776-tbl-0010){ref-type="table"}).

###### 

World Health Organization (WHO)‐recommended long‐lasting insecticidal nets (LLINs)

  ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  **Product name**   **Product type**                                                                                                                                         **Status of WHO recommendation**
  DawaPlus 2.0       Deltamethrin coated on polyester                                                                                                                         Interim
  DawaPlus 3.0       Combination of deltamethrin coated onto polyester (side panels), and deltamethrin and PBO incorporated into polyester (roof)                             Interim
  DawaPlus 4.0       Deltamethrin and PBO incorporated into polyester                                                                                                         Interim
  Duranet            Alpha‐cypermethrin incorporated into polyethylene                                                                                                        Full
  Interceptor        Alpha‐cypermethrin coated on polyester                                                                                                                   Full
  Interceptor G2     Alpha‐cypermethrin and chlorfenapyr incorporated into polyester                                                                                          Interim
  LifeNet            Deltamethrin incorporated into polypropylene                                                                                                             Interim
  MAGNet             Alpha‐cypermethrin incorporated into polyethylene                                                                                                        Full
  MiraNet            Alpha‐cypermethrin incorporated into polyethylene                                                                                                        Interim
  Olyset Net         Permethrin incorporated into polyethylene                                                                                                                Full
  Olyset Plus        Permethrin (20g/kg) and PBO (10g/kg) incorporated into polyethylene                                                                                      Interim
  Panda Net 2.0      Deltamethrin incorporated into polyethylene                                                                                                              Interim
  PermaNet 2.0       Deltamethrin coated on polyester                                                                                                                         Full
  PermaNet 3.0       Combination of deltamethrin coated on polyester with strengthened border (side panels), and deltamethrin and PBO incorporated into polyethylene (roof)   Interim
  Royal Sentry       Alpha‐cypermethrin incorporated into polyethylene                                                                                                        Full
  SafeNet            Alpha‐cypermethrin coated on polyester                                                                                                                   Full
  Veeralin           Alpha‐cypermethrin and PBO incorporated into polyethylene                                                                                                Interim
  Yahe               Deltamethrin coated on polyester                                                                                                                         Interim
  Yorkool            Deltamethrin coated on polyester                                                                                                                         Full
  ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------

Abbreviations: LLIN: long‐lasting insecticidal nets; PBO: pyrethroid‐piperonyl butoxide; WHO: World Health Organization.

###### 

World Health Organization (WHO)‐recommended insecticide products for treatment of mosquito nets for malaria vector control

  -------------------- ----------------------------------- ---------------
  **Insecticide**      **Formulation**                     **Dosage^a^**
  Alpha‐cypermethrin   SC 10%                              20‐40
  Cyfluthrin           EW 5%                               50
  Deltamethrin         SC 1%  WT 25%  WT 25% + binder^b^   15‐25
  Etofenprox           EW 10%                              200
  Lambda‐cyhalothrin   CS 2.5%                             10‐15
  Permethrin           EC 10%                              200‐500
  -------------------- ----------------------------------- ---------------

Abbreviations: EC: emulsifiable concentrate; EW: emulsion, oil in water; CS: capsule suspension; SC: suspension concentrate; WT: water dispersible tablet.  ^a^Active ingredient/netting (mg/m^2^).  ^b^K‐O TAB 1‐2‐3.

#### Control {#CD012776-sec4-0006}

Conventional LLINs that contain pyrethroid only.

For objective 1 nets of the same fabric had to be treated with the same insecticide, dose and release rate as the intervention net to allow direct evaluation of the addition of PBO.

For objective 2 (a and b), nets could be treated with the same insecticide at different doses from the intervention net to allow critical appraisal of all pyrethroid‐PBO nets currently in development or on the market.

For both intervention and control arms, nets could be unholed, holed, unwashed or washed, providing the trials adhered to WHO guidelines ([WHO 2013](#CD012776-bbs2-0055){ref-type="ref-list"}).

### Types of outcome measures {#CD012776-sec3-0004}

Trials had to include at least one of the following outcomes to be eligible for inclusion: mosquito knock‐down, mosquito mortality, blood feeding, sporozoite rate, parasite presence, clinical malaria confirmation, not passed through net, deterrence, exophily, mosquito density, or parity rate.

#### Primary outcomes {#CD012776-sec4-0007}

##### Epidemiological {#CD012776-sec5-0001}

Parasite presence: presence of malaria parasites through microscopy of blood or Rapid Diagnostic Tests (RDTs).Clinical malaria confirmation: clinical diagnosis based on the participant\'s symptoms and on physical findings at examination.

##### Entomological {#CD012776-sec5-0002}

Mosquito mortality: immediate death or delayed death (up to 24 hours), or both, measured as a proportion of total mosquito number. A mosquito is classified as dead if it is immobile, cannot stand or fly, or shows no sign of life.Mosquito knock‐down: mosquito 'mortality\' recorded one hour post‐insecticide exposure, termed 'knock‐down\' as some mosquitoes may recover during the 24‐hour recovery period before mosquito mortality is recorded at 24 hours post‐exposure.Blood‐feeding success: number of mosquitoes that have blood‐fed (alive or dead).Sporozoite rate: percentage of mosquitoes with sporozoites in salivary glands.

#### Secondary outcomes {#CD012776-sec4-0008}

##### Entomological {#CD012776-sec5-0003}

Not passed through net: the number of mosquitoes that do not pass through a holed pyrethroid‐PBO net to reach a human bait relative to a standard LLIN, using a tunnel test.Deterrence: the number of mosquitoes that enter a hut that is using a pyrethroid‐PBO net relative to the number of mosquitoes found in a control hut that is using a standard LLIN (experimental hut trials only).Exophily: the proportion of mosquitoes found in exit/veranda traps of a hut that is using a pyrethroid‐PBO net, relative to the control hut that is using a standard LLIN (experimental hut trials only).Mosquito density: measured using all standard methods, such as window exit traps, indoor resting collections, floor sheet collections, pyrethrum spray catch, and light traps (village trials).Parity rate: percentage of parous mosquitoes which are detected by mosquito ovary dissections (village trials).

Search methods for identification of studies {#CD012776-sec2-0006}
--------------------------------------------

We identified all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). We have presented the MEDLINE search strategy in [Appendix 1](#CD012776-sec2-0015){ref-type="app"}.

### Electronic searches {#CD012776-sec3-0005}

Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG) Information Specialist, searched the following databases on 24 August 2018 using the search terms and strategy described in [Appendix 1](#CD012776-sec2-0015){ref-type="app"}: the CIDG Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL, included in the Cochrane Library (Issue 8 2018); MEDLINE (PubMed); Embase (OVID); Web of Science Core Collection, and CAB Abstracts. She also searched the WHO International Clinical Trials Registry Platform (WHO ICTRP; [www.who.int/ictrp/en/](www.who.int/ictrp/en/)) and ClinicalTrials.gov ([clinicaltrials.gov/ct2/home](clinicaltrials.gov/ct2/home)) for trials in progress.

### Searching other resources {#CD012776-sec3-0006}

We contacted the following organizations for unpublished data: the PMI; the Innovative Vector Control Consortium (IVCC); Vestergaard Frandsen; Sumitomo Chemical Company Ltd; Vector Control Innovations Private Ltd; Endura SpA; and WHOPES. We checked the reference lists of trials identified by the above methods.

Data collection and analysis {#CD012776-sec2-0007}
----------------------------

All analyses were stratified by trial design. We also performed analyses for the primary outcomes stratified by both trial design and mosquito insecticide resistance level where possible. In addition, for hut trials conducted in high‐resistance areas, we also performed analyses stratified by net type.

We determined whether mosquito populations are susceptible or resistant to pyrethroid insecticides based on WHO definitions ([WHO 2016](#CD012776-bbs2-0056){ref-type="ref-list"}; [Table 11](#CD012776-tbl-0011){ref-type="table"}). We used 24‐hour mosquito mortality to determine resistance status, however if this had been unavailable, we intended to use knock‐down 60 minutes after the end of the assay. We stratified resistant populations into low‐, moderate‐, or high‐prevalence resistance ([Table 12](#CD012776-tbl-0012){ref-type="table"}), by dividing the resistant mosquitoes (that is, those with less than 90% mortality) into three equal groups, with the lower third being the most resistant and upper third the most susceptible.

###### 

Definition of resistance level

  --------------------------- -------------------------- -------------------------- ----------------- ------------------
  **Outcome**                 **Confirmed resistance**   **Suspected resistance**   **Susceptible**   **Unclassified**
  WHO mosquito mortality^a^   \< 90%                     90% to 97%                 98% to 100%       Unknown
  CDC knock‐down^b^           \< 90%                     80% to 97%                 98% to 100%       Unknown
  --------------------------- -------------------------- -------------------------- ----------------- ------------------

Abbreviations: CDC: Centers for Disease Control and Prevention; WHO: World Health Organization.  ^a^Definition of resistance level based on mosquito mortality (%) after exposure to insecticide in a WHO diagnostic dose assay.  ^b^Definition of resistance level based on mosquito mortality (%) after exposure to insecticide in a CDC bottle bioassay using the methodology, diagnostic doses, and diagnostic times recommended by each test respectively.

###### 

Stratification of resistance level

  ----------------------- ------------ -------------- ---------- ------------------
  **Outcome**             **Low**      **Moderate**   **High**   **Unclassified**
  Mosquito mortality^a^   61% to 90%   31% to 60%     \< 30%     Unknown
  ----------------------- ------------ -------------- ---------- ------------------

^a^24‐hour post‐exposure mortality (%).

### Selection of studies {#CD012776-sec3-0007}

Two review authors (KG and NL) independently screened titles and abstracts of all retrieved references based on the inclusion criteria ([Table 13](#CD012776-tbl-0013){ref-type="table"}). We resolved any inconsistencies between the review authors\' selections by discussion. If we were unable to reach an agreement, we consulted a third review author (HR). We retrieved the full‐text trial reports for all potentially relevant citations. Two review authors independently screened the full‐text articles and identified trials for inclusion, and identified and recorded reasons for exclusion of ineligible trials in a 'Characteristics of excluded studies\' table. We resolved any disagreements through discussion or, if required, consulted a third review author (HR). We identified and excluded duplicates and collated multiple reports of the same trial so that each trial, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram ([Moher 2009](Moher 2009)).

###### 

Study inclusion screening form

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- -------------- ------- -----------------------------------
  **Criteria**                                                                                                                                                                                                         **Assessment**   **Comments**           

  **Yes**                                                                                                                                                                                                              **No**           **Unclear**            

  **Mosquito population**                                                                                                                                                                                                                                      

  Did the study test *Anopheles gambiae* complex or *Anopheles funestus* group mosquitoes?                                                                                                                             **↓**            ---            **↓**   State mosquito species

  Were a minimum of 50 mosquitoes tested per study arm?                                                                                                                                                                **↓**            ---            **↓**    

  **Intervention**                                                                                                                                                                                                                                             

  Did the study include an long‐lasting insecticidal net (LLIN) or insecticide‐treated net (ITN)?                                                                                                                      **↓**            ---            **↓**   State net LLIN or ITN

  Was the intervention net either of the following?\                                                                                                                                                                   **↓**            ---            **↓**   State net type
  A piperonyl butoxide (PBO) LLIN which received a minimum of interim World Health Organization (WHO) approval.An ITN impregnated with WHO‐recommended dose of pyrethroid + PBO.                                                                               

  Was the control net either of the following?\                                                                                                                                                                        **↓**            ---            **↓**   State which objective study meets
  A pyrethroid LLIN of the same fabric impregnated with the same insecticide and dose as intervention net (objective 1).A pyrethroid LLIN impregnated with the same insecticide at any dose (objective 2 (a and b)).                                           

  **Study design**                                                                                                                                                                                                                                             

  Was the study one of the following?\                                                                                                                                                                                 **↓**            ---            **↓**   State study type
  Laboratory bioassay (cone, tunnel, ball)Experimental hut studyVillage trial                                                                                                                                                                                  

  For laboratory bioassay. Did the study use standard‐WHO protocol?                                                                                                                                                    **↓**            ---            **↓**    

  For experimental hut study and village trial. Was the study conducted in Africa?                                                                                                                                     **↓**            ---            **↓**   State country

  **Outcome**                                                                                                                                                                                                                                                  

  Did the study include at least one of the following outcome measures?\                                                                                                                                               **↓**            ---            **↓**    
  MortalityBlood feedingSporozoite rateNot passed through netDeterrenceExophilyMosquito densityParity rate                                                                                                                                                     

  **Decision**                                                                                                                                                                                                                                                 

  Is the study eligible for inclusion?                                                                                                                                                                                 ---              ---            **↓**   State reason(s) for exclusion

  Discuss with authors                                                                                                                                                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- -------------- ------- -----------------------------------

Abbreviations: ITN: insecticide‐treated net; LLIN: long‐lasting insecticidal net; PBO: piperonyl butoxide; WHO: World Health Organization.

### Data extraction and management {#CD012776-sec3-0008}

After selection, we summarized all included trials according to the tables in [Appendix 2](#CD012776-sec2-0016){ref-type="app"}. Two review authors (KG and NL) independently extracted data from the included trials using the pre‐designed data extraction form ([Appendix 3](#CD012776-sec2-0017){ref-type="app"}). If data were missing from an included trial, we contacted the trial authors for further information. We entered data into Review Manager 5 (RevMan 5) ([Review Manager 2014](#CD012776-bbs2-0047){ref-type="ref-list"}).

### Assessment of risk of bias in included studies {#CD012776-sec3-0009}

Two review authors (KG and NL) independently assessed the risk of bias of each included trial using a set of predetermined criteria specific to each trial type adapted from [Strode 2014](#CD012776-bbs2-0052){ref-type="ref-list"} ([Appendix 4](#CD012776-sec2-0018){ref-type="app"}). We assigned a classification of either low, high, or unclear risk of bias for each component. For all included trials we assessed whether any trial authors had submitted any conflicts of interest that may have biased the trial methodology or results.

#### Laboratory bioassays {#CD012776-sec4-0009}

For laboratory bioassays we assessed five criteria: comparability of mosquitoes between LLIN/pyrethroid‐PBO net arms (for example, all female, same age, and non‐blood‐fed), observers blinded, incomplete outcome data, raw data reported for both net treatments, and trial authors\' conflicting interests.

#### Experimental hut trials {#CD012776-sec4-0010}

For experimental hut trials we assessed 11 criteria: comparability of mosquitoes between LLIN/pyrethroid‐PBO net arms (for example, species composition), collectors blinded, sleepers blinded, sleeper bias accounted for, treatment allocation, treatment rotation, standardized hut design, hut cleaning between treatments, incomplete outcome data, raw data reported, and trial authors\' conflicting interests.

#### Village trials {#CD012776-sec4-0011}

We assessed 12 criteria for village trials: recruitment bias, comparability of mosquitoes between LLIN/pyrethroid‐PBO net households (for example, species composition), collectors blinded, household blinded, treatment allocation, allocation concealment, incomplete outcome data, raw data reported, clusters lost to follow‐up, selective reporting, adjusting for data clustering, and trial authors\' conflicting interests.

### Measures of treatment effect {#CD012776-sec3-0010}

For dichotomous data we presented the risk ratio (RR). There were no continuous or count data; however if there had been, we would have used the mean difference and rate ratios, respectively. We have presented all results with 95% confidence intervals (CIs).

### Unit of analysis issues {#CD012776-sec3-0011}

For trials randomized by hut or village, we used the adjusted measure of effect reported in the paper if available. If not reported, we adjusted the effect estimate using an intracluster correlation coefficient (ICC), and average cluster size ([Higgins 2011](#CD012776-bbs2-0034){ref-type="ref-list"}, Section 16.3.4). If the included trial did not report the ICC value, we estimated the ICC value and investigated the impact of estimating the ICC in sensitivity analyses.

To adjust results of experimental hut trials for clustering, we treated each 'hut and sleeper\' combination as the unit of analysis, as each 'hut and sleeper\' combination was tested with each type of net, over a series of nights. We calculated effective sample sizes by estimating an ICC and corresponding design effect. We divided both the number of mosquitoes and the number experiencing the event by this design effect.

To adjust results of village trials for clustering (for which the trial authors had not adjusted the data themselves), we treated each village as the unit of analysis. We calculated effective sample sizes by estimating an ICC and corresponding design effect. Forest plots for both hut and village trials show the effective number of events after adjusting for clustering.

### Dealing with missing data {#CD012776-sec3-0012}

In the case of missing data, we contacted the trial authors to retrieve this information. If we had identified trials where participants were lost to follow‐up, we would have investigated the impact of missing data via imputation using a best‐worst case scenario analysis.

Where information on mosquito insecticide resistance was not collected at the time of the trial, the review authors determined a suitable proxy. The proxy resistance data had to be from the same area, conducted within three years of the trial, and using the same insecticide, dose, and mosquito species. More than 50 mosquitoes per insecticide should have been tested using an appropriate control. Where no resistance data were available, we classed the resistance status as unclassified.

### Assessment of heterogeneity {#CD012776-sec3-0013}

We presented the results of the included trials in forest plots, which we inspected visually to assess heterogeneity (that is, non‐overlapping CIs generally signify statistical heterogeneity). We also used the Chi^2^ test with a P value of less than 0.1 to indicate statistical heterogeneity. We quantified heterogeneity using the I^2^ statistic ([Higgins 2003](#CD012776-bbs2-0033){ref-type="ref-list"}), and we interpreted a value greater than 75% to indicate considerable heterogeneity ([Deeks 2017](#CD012776-bbs2-0029){ref-type="ref-list"}).

### Assessment of reporting biases {#CD012776-sec3-0014}

To analyse the possibility of publication bias, we intended to use funnel plots if 10 trials were included in any of the meta‐analyses. However, no analyses included 10 or more trials, so this was not applicable.

### Data synthesis {#CD012776-sec3-0015}

Where appropriate, we pooled the results of the included trials using meta‐analysis. We stratified results by type of trial, mosquito resistance status and net type (i.e. product, for example Olyset Plus).

Three review authors (KG, NL, and MR) analysed the data using RevMan 5 ([Review Manager 2014](#CD012776-bbs2-0047){ref-type="ref-list"}), and we used the random‐effects model (if we detected heterogeneity; the I^2^ statistic value was more than 75%), or the fixed‐effect model (for no heterogeneity; the I^2^ statistic value was less than 75%). We would have not pooled trials in meta‐analysis if it was not clinically meaningful to do so, due to clinical or methodological heterogeneity.

### Subgroup analysis and investigation of heterogeneity {#CD012776-sec3-0016}

We performed subgroup analyses according to whether nets were washed or unwashed.

### Sensitivity analysis {#CD012776-sec3-0017}

We intended to perform sensitivity analyses to determine the effect of exclusion of trials that we considered to be at high risk of bias, however this was not applicable. We would also have performed a sensitivity analysis for missing data during imputation with best‐worst case scenarios, but again this was not applicable.

We performed sensitivity analyses to investigate the impact of estimating an ICC to adjust trial results for clustering. We performed analyses using ICCs of 0.01, 0.05, and 0.1. Since the results were robust to these adjustments, we used the most conservative ICC (0.1), and we adjusted all results from unadjusted cluster trials using this ICC. We have not presented analyses using the smaller ICCs (0.01 and 0.05).

#### Certainty of the evidence {#CD012776-sec4-0012}

We assessed the certainty of the evidence using the GRADE approach ([Schünemann 2013](#CD012776-bbs2-0050){ref-type="ref-list"}). We constructed 'Summary of findings\' tables using the GRADEpro Guideline Development Tool (GDT) software ([GRADEpro GDT 2015](#CD012776-bbs2-0031){ref-type="ref-list"}).

Results {#CD012776-sec1-0005}
=======

Description of studies {#CD012776-sec2-0008}
----------------------

### Results of the search {#CD012776-sec3-0018}

We identified 168 records through the electronic searches, and 19 additional records from other sources. We removed duplicates, leaving 175 records, and screened all articles for possible inclusion. After abstract and title screening, we excluded 154 obviously ineligible trials. We assessed 22 full‐text articles for eligibility and excluded seven articles for the following reasons: five trials did not share the full datasets and two studies are ongoing. Fifteen trials met the inclusion criteria ([Figure 1](#CD012776-fig-0001){ref-type="fig"}).

![Study flow diagram](nCD012776-AFig-FIG01){#CD012776-fig-0001}

### Included studies {#CD012776-sec3-0019}

Fifteen trials met the inclusion criteria, and we have described them in the '[Characteristics of included studies](#CD012776-sec2-0024){ref-type="sec"}\' tables. Two trials were laboratory bioassays ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}), eight trials were experimental hut trials ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"} (Burkina Faso); [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"} (Burkina Faso, Benin, Cameroon); [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"} (Côte d\'Ivoire); [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"} (Tanzania); [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"} (Benin); [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"} (Benin); [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"} (Burkina Faso); [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"} (Tanzania)), and five trials were village trials ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"} (Nigeria); [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"} (Mali); [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"} (Malawi); [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"} (Tanzania); [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"} (Ghana)). All trials were conducted in Africa.

#### Interventions {#CD012776-sec4-0013}

Two trials compared a net treated with deltamethrin to a net treated with deltamethrin and PBO ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}). Six trials compared Permanet 2.0 to Permanet 3.0 ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}). Two trials compared Olyset Net to Olyset Plus ([Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}). One trial compared MAGNet LN to Veeralin LN ([Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}). Three trials compared both Olyset Net to Olyset Plus and Permanet 2.0 to Permanet 3.0 ([Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}). One trial compared DawaPlus 2.0 to DawaPlus 3.0 and DawaPlus 4.0 ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}).

### Excluded studies {#CD012776-sec3-0020}

We assessed 22 full‐text articles for eligibility and excluded seven articles for the following reasons: five trials are awaiting classification because we were unable to obtain the full data sets after we contacted the trial authors (see '[Characteristics of studies awaiting classification](#CD012776-sec2-0025){ref-type="sec"}\' table), and two trials are ongoing (see '[Characteristics of ongoing studies](#CD012776-sec2-0026){ref-type="sec"}\' section).

Risk of bias in included studies {#CD012776-sec2-0009}
--------------------------------

We have provided a 'Risk of bias\' assessment summary in [Figure 2](#CD012776-fig-0002){ref-type="fig"}. The criteria we used to assess risk of bias are in [Appendix 5](#CD012776-sec2-0019){ref-type="app"} (laboratory bioassays), [Appendix 6](#CD012776-sec2-0020){ref-type="app"} (experimental hut trials), and [Appendix 7](#CD012776-sec2-0021){ref-type="app"} (village trials).

!['Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included study.](nCD012776-AFig-FIG02){#CD012776-fig-0002}

### Allocation {#CD012776-sec3-0021}

#### Recruitment bias {#CD012776-sec4-0014}

We assessed all five village trials as at low risk of bias. Four village trials were at low risk of recruitment bias as recruitment bias is related to human participants and so not applicable to this review ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}). We assessed one village trial as low risk as no participants were recruited after clusters had been randomized ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}).

#### Mosquito group comparability {#CD012776-sec4-0015}

We judged the two laboratory bioassays at low risk of bias ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}), as they used the same mosquito strain, and all eight experimental hut trials at low risk ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), as the huts were situated in the same trial area and therefore accessible to the same mosquito populations. We judged four village trials at unclear risk ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}), as the species composition and resistance status varied slightly between treatment arms. We deemed one village trial high risk ([Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}), as species and resistance data were not separated by village, and it was not possible to ascertain this from the information provided.

### Blinding {#CD012776-sec3-0022}

We assessed the two laboratory trials ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}), and eight hut trials ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), as at unclear risk as they did not specify whether observers (lab trials), or collectors and sleepers (hut trials) were blinded. This is not standard protocol for these trial designs and is thought unlikely to affect the results. We judged four village trials at high risk of bias, as it was not stated if collectors were blinded, and this may affect searching effort during collections ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}). We classed one trial as low risk because collectors were masked to the treatment ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}). For household blinding we judged all five village trials as low risk of bias. Four village trials did not state if households were blind to the intervention, however this was unlikely to influence the results ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}). We judged one village trial as low risk, as inhabitants and field collectors were blinded to intervention arms ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}).

#### Sleeper bias {#CD012776-sec4-0016}

We assessed the eight hut trials at low risk for sleeper bias, as sleepers were rotated between huts following a Latin square design ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}).

#### Treatment allocation, rotation, and concealment {#CD012776-sec4-0017}

We assessed the eight hut trials at low risk for treatment allocation and rotation ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), as treatments were rotated between huts following a Latin square design. We assessed five village trials at low risk for treatment allocation ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}), as villages were randomly assigned to treatment arms. We assessed all five village trials as low risk of bias for allocation concealment ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}).

#### Hut design {#CD012776-sec4-0018}

We assessed eight hut trials at low risk of bias, as huts were built to standard West‐ or East‐African specifications ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), or using modified but standardized designs ([Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}).

#### Cleaning {#CD012776-sec4-0019}

We assessed four hut trials at unclear risk as they did not state if huts were cleaned between treatment arms ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}). We assessed four at low risk, as cleaning was conducted between treatment rotations ([Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}).

### Incomplete outcome data {#CD012776-sec3-0023}

We assessed all laboratory ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}), hut ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), and village trials ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}), as at low risk for both incomplete outcome data and raw data reporting, as there were no incomplete outcome data, or missing data were later provided by the trial authors. In cases where raw data were not reported, we were able to calculate them from the percentages and sample sizes given. When these data were not available, we did not include the trials.

#### Clustering bias {#CD012776-sec4-0020}

No clusters were lost to follow‐up in any of the village trials, therefore we assessed all village trials as at low risk of bias ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}). We assessed four village trials as at high risk of bias for statistical methods used, as they did not adjust for clustering ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}). We assessed one trial as low risk of bias, as it took clustering into account and adjusted for it in its statistical methods ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}).

### Selective reporting {#CD012776-sec3-0024}

We assessed all village trials as low risk of bias regarding selective reporting, as they appear to have reported all measured outcomes ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}).

### Other potential sources of bias {#CD012776-sec3-0025}

#### Conflicting interests {#CD012776-sec4-0021}

We judged two lab trials ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}), seven hut trials ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), and three village trials ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}), as at low risk as the trial authors reported no conflicting interests. We assessed one hut trial at unclear risk ([N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}), as the trial authors stated that they had received funding from LLIN manufacturers when conducting the trials, and the same funders also provided comments on the manuscript. We assessed one village trial as unclear risk, as the trial authors did not state if there were conflicting interests or not ([Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}), and another one as unclear risk, as the trial was conducted to form part of the manufacturer\'s product dossier ([Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}).

Effects of interventions {#CD012776-sec2-0010}
------------------------

See: [Table 1](#CD012776-tbl-0001){ref-type="table"}; [Table 2](#CD012776-tbl-0002){ref-type="table"}; [Table 3](#CD012776-tbl-0003){ref-type="table"}; [Table 4](#CD012776-tbl-0004){ref-type="table"}

### Objective 1 {#CD012776-sec3-0026}

Objective 1 was to evaluate whether adding PBO to pyrethroid‐LLINs increases the epidemiological and entomological effectiveness of bed nets.

#### Epidemiological results {#CD012776-sec4-0022}

None of the trials that met the inclusion criteria for Objective 1 measured parasite presence, or clinical malaria confirmation, in adults or children.

#### Entomological results {#CD012776-sec4-0023}

Two laboratory trials evaluated the impact of an insecticide‐treated net (ITN), impregnated with deltamethrin (a pyrethroid insecticide), only, compared to ITN plus PBO (PBO‐ITN), on mosquito mortality in an insecticide‐resistant laboratory strain ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}). The pooled analysis showed substantially increased mosquito mortality when using pyrethroid‐PBO (RR 6.06, 95% CI 4.15 to 8.84; 558 mosquitoes, 2 trials; [Analysis 1.1](#CD012776-fig-00101){ref-type="fig"}).

### Objective 2 {#CD012776-sec3-0027}

Objective 2 compared the effects of pyrethroid‐PBO nets currently in commercial development or on the market with their non‐PBO equivalent in relation to malaria infection and entomological outcomes.

#### Epidemiological results {#CD012776-sec4-0024}

One trial examined the effect of pyrethroid‐PBO nets on malaria infection prevalence ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}). Overall the latest endpoint at 21 months after the intervention showed that malaria prevalence decreased in the intervention arm (OR 0.40, 95% CI 0.20 to 0.80; 1 trial, 1 comparison; [Analysis 3.1](#CD012776-fig-00301){ref-type="fig"}).

#### Entomological results {#CD012776-sec4-0025}

##### Phase II experimental hut trials {#CD012776-sec5-0004}

Eight experimental hut trials (phase II trials), examined the effect of pyrethroid‐PBO nets on mosquito mortality, blood feeding, exophily, and deterrence ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}). We subgrouped the data by net washing, into unwashed and washed groups. Washed nets were all washed 20 times according to WHO specifications ([WHO 2013](#CD012776-bbs2-0055){ref-type="ref-list"}). We pooled the results initially and then stratified them by insecticide resistance level and net type. One trial did not wash their nets and so did not report any data for the washed subgroup ([Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}). One trial did not introduce holes into the nets and so did not report blood‐feeding success data ([Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}).

###### Pooled *a*nalysis {#CD012776-sec6-0001}

Pooled analysis of all experimental hut trials, using both unwashed ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}) and washed nets ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), found that pyrethroid‐PBO nets significantly increased mosquito mortality, by 36% (RR 1.36, 95% CI 1.20 to 1.54), and reduced blood‐feeding success by 24% (RR 0.76, 95% CI 0.67 to 0.88). The magnitude of effect was reduced by net washing. Unwashed pyrethroid‐PBO nets increased mosquito mortality by 54% compared to unwashed LLINs, (RR 1.54, 95% CI 1.21 to 1.96; 8 trials, 15 comparisons; [Analysis 2.1](#CD012776-fig-00201){ref-type="fig"}); when nets are washed this effect decreased to 14%, (RR 1.14, 95% 1.00 to 1.31; 7 trials, 11 comparisons; [Analysis 2.1](#CD012776-fig-00201){ref-type="fig"}). Unwashed pyrethroid‐PBO nets reduced mosquito blood‐feeding success by 34% ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}; RR 0.66, 95% CI 0.54 to 0.79; 7 trials, 14 comparisons; [Analysis 2.2](#CD012776-fig-00202){ref-type="fig"}); however this effect was lost when nets were washed ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}; 6 trials, 10 comparisons; [Analysis 2.2](#CD012776-fig-00202){ref-type="fig"}). There was no effect on mosquito exophily in either unwashed (8 trials, 15 comparisons; [Analysis 2.3](#CD012776-fig-00203){ref-type="fig"}) or washed (7 trials, 11 comparisons; [Analysis 2.3](#CD012776-fig-00203){ref-type="fig"}), groups. Mosquito deterrence data were presented relative to an untreated control and hence are not included as a forest plot. There was considerable variation in the deterrence rates but no clear relationship with resistance level, net type, or washing status ([Table 14](#CD012776-tbl-0014){ref-type="table"}).

###### 

Experimental hut trials: deterrence data

  ------------------------------------------------------------- --------------- -------------- ---------------- ----------------------------- ----------------------------- ----------------------------- -------------------------------
  **Study ID**                                                  **Locality**    **Net type**   **Net washed**   **Total number in ITN hut**   **Total number in UTN hut**   **Deterrence (%) reported**   **Deterrence (%) calculated**
  [Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}       Vallée du Kou   DawaPlus 2.0   No               1548                          1848                          16.23                         16.23
  [Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}       Vallée du Kou   DawaPlus 2.0   Yes              2155                          1848                          0                             ‐16.61
  [Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}       Vallée du Kou   DawaPlus 3.0   No               1365                          1848                          26.13                         26.14
  [Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}       Vallée du Kou   DawaPlus 3.0   Yes              1981                          1848                          0                             ‐7.20
  [Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}       Vallée du Kou   DawaPlus 4.0   No               846                           1848                          54.22                         54.22
  [Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}       Vallée du Kou   DawaPlus 4.0   Yes              1646                          1848                          10.93                         10.93
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Malanville      Permanet 2.0   Yes              195                           285                           31.58                         31.58
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Malanville      Permanet 3.0   Yes              210                           285                           26.32                         26.32
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Malanville      Permanet 2.0   No               243                           285                           14.74                         14.74
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Malanville      Permanet 3.0   No               214                           285                           24.91                         24.91
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Pitoa           Permanet 2.0   Yes              310                           401                           22.69                         22.69
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Pitoa           Permanet 3.0   Yes              163                           401                           59.35                         59.35
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Pitoa           Permanet 2.0   No               105                           401                           73.82                         73.82
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Pitoa           Permanet 3.0   No               146                           401                           63.59                         63.59
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Vallée du Kou   Permanet 2.0   Yes              788                           908                           13.22                         13.22
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Vallée du Kou   Permanet 3.0   Yes              724                           908                           20.26                         20.26
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Vallée du Kou   Permanet 2.0   No               329                           908                           63.77                         63.77
  [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}       Vallée du Kou   Permanet 3.0   No               463                           908                           49.01                         49.01
  [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}       Yaokoffikro     Permanet 3.0   No               303                           796                           62.1                          61.93
  [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}       Yaokoffikro     Permanet 2.0   No               317                           796                           60.4                          60.18
  [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}       Yaokoffikro     Permanet 3.0   Yes              313                           796                           60.1                          60.68
  [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}       Yaokoffikro     Permanet 2.0   Yes              281                           796                           64.4                          64.70
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         Veeralin LN    No               722                           810                           11                            10.86
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         Veeralin LN    Yes              727                           810                           10                            10.25
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         MAGNet LN      No               1070                          810                           0                             ‐32.10
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         MAGNet LN      Yes              773                           810                           5                             4.57
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         Veeralin LN    No               89                            170                           48                            47.65
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         Veeralin LN    Yes              85                            170                           50                            50.00
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         MAGNet LN      No               114                           170                           33                            32.94
  [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}        Ifakara         MAGNet LN      Yes              103                           170                           39                            39.41
  [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}   Akron           Permanet 3.0   No               128                           185                           31                            30.81
  [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}   Akron           Permanet 3.0   Yes              155                           185                           NR                            16.22
  [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}   Akron           Permanet 2.0   No               114                           185                           38                            38.38
  [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}   Akron           Permanet 2.0   Yes              174                           185                           NR                            5.95
  [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}    Malanville      Olyset Plus    No               67                            69                            NR                            2.90
  [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}    Malanville      Olyset Plus    Yes              101                           69                            NR                            ‐46.38
  [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}    Malanville      Olyset Net     No               96                            69                            NR                            ‐39.13
  [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}    Malanville      Olyset Net     Yes              124                           69                            NR                            ‐79.71
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          Tengrela        Olyset Net     No               923                           480                           ‐92.29                        ‐92.29
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          Tengrela        Olyset Plus    No               695                           480                           ‐44.79                        ‐44.79
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          Tengrela        Permanet 2.0   No               858                           480                           ‐78.75                        ‐78.75
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          Tengrela        Permanet 3.0   No               794                           480                           ‐65.42                        ‐65.42
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          VK5             Olyset Net     No               1458                          1095                          ‐33.15                        ‐33.15
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          VK5             Olyset Plus    No               1278                          1095                          ‐16.71                        ‐16.71
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          VK5             Permanet 2.0   No               1075                          1095                          1.83                          1.83
  [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}          VK5             Permanet 3.0   No               657                           1095                          40                            40.00
  [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}        Zeneti          PermaNet 3.0   No               425                           723                           41                            41.22
  [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}        Zeneti          PermaNet 2.0   No               574                           723                           21                            20.61
  [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}        Zeneti          PermaNet 3.0   Yes              558                           723                           23                            22.82
  [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}        Zeneti          PermaNet 2.0   Yes              586                           723                           19                            18.95
  ------------------------------------------------------------- --------------- -------------- ---------------- ----------------------------- ----------------------------- ----------------------------- -------------------------------

Abbreviations: ITN: insecticide‐treated net; LLIN: long‐lasting insecticidal net; NR: not reported; PBO: piperonyl butoxide; UTN: untreated net; WHO: World Health Organization.

There was considerable heterogeneity in this pooled analysis, particularly for estimates of mortality. We therefore performed a pre‐specified, stratified analysis, dividing the results into trials conducted in areas of low, moderate, or high resistance in the *Anopheles* population.

###### Stratified analysis: mosquito resistance status {#CD012776-sec6-0002}

We used the WHO and CDC definitions of mosquito mortality, from WHO tube assays or CDC bottle tests ([Table 11](#CD012776-tbl-0011){ref-type="table"}) to classify mosquito resistance. Both tests define mosquitoes as resistant when mortality is less than 90%. We further stratified resistance based on the following mortality levels: \< 30%, high resistance; 31% to 60%, moderate resistance; 61% to 90%, low resistance ([Table 12](#CD012776-tbl-0012){ref-type="table"}). When resistance data were not collected at the time of the trial, we identified a suitable proxy based on previously described criteria (see '[Dealing with missing data](#CD012776-sec3-0012){ref-type="sec"}\' section); when we could not identify a suitable proxy, we classed the trial as 'unclassified\' and did not include it in the resistance stratification.

Five trials were conducted in four areas where mosquito populations exhibited high resistance to pyrethroids ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}). Under these conditions unwashed pyrethroid‐PBO nets increased mosquito mortality by 84% in comparison to unwashed LLINs (RR 1.84, 95% CI 1.60 to 2.11; 5 trials, 9 comparisons; [Analysis 2.4](#CD012776-fig-00204){ref-type="fig"}), however this effect was lost when nets were washed ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; 4 trials, 5 comparisons; [Analysis 2.4](#CD012776-fig-00204){ref-type="fig"}). Blood‐feeding success was reduced by 40% in unwashed pyrethroid‐PBO‐net groups compared to unwashed LLINs ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; RR 0.60, 95% CI 0.50 to 0.71; 4 trials, 8 comparisons; [Analysis 2.5](#CD012776-fig-00205){ref-type="fig"}), and by 19% when nets were washed ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; RR 0.81, 95% CI 0.72 to 0.92; 3 trials, 4 comparisons; [Analysis 2.5](#CD012776-fig-00205){ref-type="fig"}).

One trial in one site was conducted in an area with moderate insecticide resistance ([N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}). No effect on mosquito mortality (1 trial, 1 comparison; [Analysis 2.6](#CD012776-fig-00206){ref-type="fig"}) or on blood‐feeding success (1 trial, 1 comparison; [Analysis 2.7](#CD012776-fig-00207){ref-type="fig"}) was observed in either washed or unwashed treatments.

One trial in two sites was conducted in an area with low insecticide resistance ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}). A small effect on mosquito mortality was observed in unwashed nets (RR 1.10, 95% CI 1.05 to 1.16; 1 trial, 2 comparisons; [Analysis 2.8](#CD012776-fig-00208){ref-type="fig"}), however this was lost by washing (1 trial, 2 observations; [Analysis 2.8](#CD012776-fig-00208){ref-type="fig"}). No effect was seen in blood‐feeding success (1 trial, 2 comparisons; [Analysis 2.9](#CD012776-fig-00209){ref-type="fig"}).

In susceptible sites ([Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), no effect on mosquito mortality (2 trials, 2 comparisons; [Analysis 2.10](#CD012776-fig-00210){ref-type="fig"}), or blood‐feeding success (2 trials, 2 comparisons; [Analysis 2.11](#CD012776-fig-00211){ref-type="fig"}), was observed.

###### Stratified analysis: net *t*ype {#CD012776-sec6-0003}

After stratifying by resistance status, we performed a secondary analysis stratified according to net type. Due to the limited number of trials, we only performed this analysis for trials using PermaNet 3.0 or Olyset Plus. Although additional trials utilising Veeralin LN, DawaPlus 3.0, and DawaPlus 4.0 have been conducted, not all data were made available to us for the purposes of this Cochrane Review. Futhermore, the analysis was restricted to trials conducted in areas of high resistance, as this analysis only indicated an impact of pyrethroid‐PBO nets in these settings. Three trials compared PermaNet 2.0 (LLIN) to PermaNet 3.0 (pyrethroid‐PBO nets), and two compared Olyset Nets (LLIN) to Olyset Plus (pyrethroid‐PBO nets).

In the PermaNet group, in high‐resistance settings, unwashed PermaNet 3.0 increased mosquito mortality by 81% compared to PermaNet 2.0 ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; RR 1.81, 95% CI 1.56 to 2.10; 3 trials, 4 comparisons; [Analysis 2.12](#CD012776-fig-00212){ref-type="fig"}). After washing there was no significant increase in mortality in the PermaNet 3.0 arm ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; 2 trials, 2 comparisons; [Analysis 2.12](#CD012776-fig-00212){ref-type="fig"}). Blood‐feeding success was reduced by 47% when using unwashed PermaNet 3.0 ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; RR 0.53, 95% CI 0.40 to 0.69; 2 trials, 3 comparisons; [Analysis 2.13](#CD012776-fig-00213){ref-type="fig"}), only one trial was available for washed nets ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}), and here PermaNet 3.0 also reduced blood‐feeding success (RR 0.76, 95% 0.61 to 0.93; 1 trial, 1 comparison; [Analysis 2.13](#CD012776-fig-00213){ref-type="fig"}).

In high‐resistance settings, Olyset Plus increased mosquito mortality by 72% when nets were unwashed ([Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; RR 1.72, 95% CI 1.48 to 1.99; 2 trials, 3 comparisons; [Analysis 2.14](#CD012776-fig-00214){ref-type="fig"}). Only one trial compared washed Olyset Plus with washed Olyset ([Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}); in this trial the enhanced mortality (81%) in the Olyset Plus arm was still observed after washing (RR 1.81, 95% CI 1.25 to 2.61; 1 trial, 1 comparison; [Analysis 2.14](#CD012776-fig-00214){ref-type="fig"}). There was no impact on blood‐feeding success when comparing unwashed Olyset Plus with Olyset (2 trials, 3 comparisons; [Analysis 2.15](#CD012776-fig-00215){ref-type="fig"}); the single trial that looked at washed Olyset Plus showed decreased blood feeding compared to Olyset (RR 0.50, 95% 0.27 to 0.93; 1 trial, 1 comparison; [Analysis 2.15](#CD012776-fig-00215){ref-type="fig"})

##### Phase III village trials {#CD012776-sec5-0005}

In the village trials there was no decrease in sporozoite rate in the trial arms receiving pyrethroid‐PBO nets ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}; RR 0.82, 95% CI 0.24 to 2.75; 4 trials, 5 comparisons; [Analysis 3.2](#CD012776-fig-00302){ref-type="fig"}). Mosquito parity was not reduced in pyrethroid‐PBO villages ([Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}; 3 trials, 4 comparisons; [Analysis 3.3](#CD012776-fig-00303){ref-type="fig"}). It was not possible to stratify these data by resistance status due to the variability in resistance levels between villages within the same trial. Mosquito density was measured using a variety of methods and summarized in different ways (for example, mean number caught per house, mean number caught per village). Where baseline data were collected, we calculated a percentage reduction. Higher reductions in mosquito densities were observed in pyrethroid‐PBO net villages compared to LLIN villages ([Table 15](#CD012776-tbl-0015){ref-type="table"}).

###### 

Village trials: mosquito density data

  --------------------------------------------------------------- -------------------- --------------------- ----------------------------------------------------- ----------------------- ---------------------- ------------------------------- -------------------
  **Study ID**                                                    **Net type**         **Species**           **Density measurement**                               **Collection method**   **Baseline density**   **Post‐intervention density**   **Reduction (%)**
  [Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}        Untreated            *An gambiae* s.l.     Mean number caught per house                          WT, IRC                 16.2                   17.1                            ‐5.56
  [Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}        PermaNet 2.0         *An gambiae* s.l.     Mean number caught per house                          WT, IRC                 21.3                   7.2                             66.20
  [Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}        PermaNet 3.0         *An gambiae* s.l.     Mean number caught per house                          WT, IRC                 20.1                   1.4                             93.03
  [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}          PermaNet 2.0         *An gambiae* s.l.     Resting density per room per day                      IRC                     ‐                      1.92                            ‐
  [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}          PermaNet 3.0         *An gambiae* s.l.     Resting density per room per day                      IRC                     ‐                      3.05                            ‐
  [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}          Olyset               *An gambiae* s.l.     Resting density per room per day                      IRC                     ‐                      3.21                            ‐
  [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}          Olyset Plus          *An gambiae* s.l.     Resting density per room per day                      IRC                     ‐                      3.7                             ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olyset               *An gambiae*          Mean number caught per catch                          PSC                     ‐                      0.10                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olset Plus           *An gambiae*          Mean number caught per catch                          PSC                     ‐                      0.12                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 2.0         *An gambiae*          Mean number caught per catch                          PSC                     ‐                      0.13                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 3.0         *An gambiae*          Mean number caught per catch                          PSC                     ‐                      0.09                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olyset               *An funestus*         Mean number caught per catch                          PSC                     ‐                      0.08                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olyset Plus          *An funestus*         Mean number caught per catch                          PSC                     ‐                      0.16                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 2.0         *An funestus*         Mean number caught per catch                          PSC                     ‐                      0.27                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 3.0         *An funestus*         Mean number caught per catch                          PSC                     ‐                      0.13                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olyset               *An gambiae*          Mean number caught per catch                          LT                      ‐                      1.23                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olset Plus           *An gambiae*          Mean number caught per catch                          LT                      ‐                      0.27                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 2.0         *An gambiae*          Mean number caught per catch                          LT                      ‐                      0.96                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 3.0         *An gambiae*          Mean number caught per catch                          LT                      ‐                      1.44                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olyset               *An funestus*         Mean number caught per catch                          LT                      ‐                      2.02                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      Olset Plus           *An funestus*         Mean number caught per catch                          LT                      ‐                      2.1                             ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 2.0         *An funestus*         Mean number caught per catch                          LT                      ‐                      5.76                            ‐
  [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}      PermaNet 3.0         *An funestus*         Mean number caught per catch                          LT                      ‐                      3.76                            ‐
  [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}    Olyset (2015)        *Anopheles* species   Mean number caught per house per night                LT                      ‐                      2.61                            ‐
  [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}    Olyset Plus (2015)   *Anopheles* species   Mean number caught per house per night                LT                      ‐                      1.85                            ‐
  [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}    Olyset (2016)        *Anopheles* species   Mean number caught per house per night                LT                      ‐                      3.60                            ‐
  [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}    Olyset Plus (2016)   *Anopheles* species   Mean number caught per house per night                LT                      ‐                      2.68                            ‐
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   No intervention      *An gambiae* s.s.     Mean number caught per village                        IRC                     230                    79                              65.65
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 2.0         *An gambiae* s.s.     Mean number caught per village                        IRC                     39                     36                              7.69
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 2.0         *An gambiae* s.s.     Mean number caught per village                        IRC                     82                     45                              45.12
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 3.0         *An gambiae* s.s.     Mean number caught per village                        IRC                     77                     12                              84.42
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 3.0         *An gambiae* s.s.     Mean number caught per village                        IRC                     178                    15                              91.57
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   No intervention      *An gambiae* s.s.     Mean number caught per person per night per village   Indoor & outdoor HLC    415                    72                              82.65
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 2.0         *An gambiae* s.s.     Mean number caught per person per night per village   Indoor & outdoor HLC    33                     31                              6.06
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 2.0         *An gambiae* s.s.     Mean number caught per person per night per village   Indoor & outdoor HLC    79                     64                              18.99
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 3.0         *An gambiae* s.s.     Mean number caught per person per night per village   Indoor & outdoor HLC    98                     19                              80.61
  [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}   Permanet 3.0         *An gambiae* s.s.     Mean number caught per person per night per village   Indoor & outdoor HLC    156                    36                              76.92
  --------------------------------------------------------------- -------------------- --------------------- ----------------------------------------------------- ----------------------- ---------------------- ------------------------------- -------------------

Abbreviations: *An gambiae*: *Anopheles gambiae*; *An funestus*: *Anopheles funestus*; HLC: human landing catch; IRC: indoor resting catch; LT: light trap; PSC: pyrethrum spray catch; WT: window trap.

Discussion {#CD012776-sec1-0006}
==========

See [Table 1](#CD012776-tbl-0001){ref-type="table"}, [Table 2](#CD012776-tbl-0002){ref-type="table"}, [Table 3](#CD012776-tbl-0003){ref-type="table"}, and [Table 4](#CD012776-tbl-0004){ref-type="table"}.

Summary of main results {#CD012776-sec2-0011}
-----------------------

There was a single cluster‐RCT performed on pyrethroid‐PBO nets. This trial, which compared malaria prevalence in children using Olyset Plus nets with those using Olyset nets, in a region of Tanzania where the mosquito vectors are highly resistant to pyrethroids, found that pyrethroid‐PBO nets reduced malaria prevalence by 60% ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}). All other trials included in this review measured entomological endpoints. Four villages measured sporozoite rates in mosquitoes collected from houses using pyrethroid‐PBO nets and standard pyrethroid LLINs but the results were highly heterogeneous and there was no evidence that pyrethroid‐PBO nets reduced the mosquito infection rate from this pooled analysis ([Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}; [Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}). Similarly, the proportion of parous mosquitoes (that is, mosquitoes that have survived past one gonotrophic cycle, used as an indirect measure of longevity), was not significantly affected by the presence of pyrethroid‐PBO nets ([Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}; [Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}; [Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}).

When we pooled the results from the eight experimental hut trials ([Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}; [Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}; [Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}), the results showed an improved performance of pyrethroid‐PBO LLINs over standard LLINs in both increasing mosquito mortality and reducing blood feeding but the results were highly heterogeneous. Stratifying the experimental hut data by resistance levels in the population reduced the heterogeneity. In areas where mosquitoes are highly resistant to pyrethroids, pyrethroid‐PBO nets will reduce mosquito blood‐feeding rates (that is, users of the nets will be better protected against mosquito bites by using pyrethroid‐PBO nets). This impact on blood feeding is reduced when nets have been through the standard 20 washes recommended by the WHO to assess chemical durability, but remains significant (high‐certainty evidence). When resistance is high and new unwashed nets are used, mosquito mortality is substantially increased when the nets contain PBO compared to pyrethroid‐only LLINs (high‐certainty evidence*)*. However this effect on mosquito mortality, which is important for the community‐level protection afforded by LLIN usage ([Hawley 2003](#CD012776-bbs2-0032){ref-type="ref-list"}; [Maxwell 2002](#CD012776-bbs2-0039){ref-type="ref-list"}), is not sustained when nets have been washed multiple times. In this Cochrane Review we classified mosquitoes as being highly resistant if fewer than 30% were killed in a standard bioassay. When mortality rates exceeded 30%, there was little evidence that pyrethroid‐PBO nets provided greater personal protection or resulted in greater mosquito mortality than standard pyrethroid‐only nets. This result is not unexpected given that, in areas where resistance is uncommon or absent, exposure to pyrethroids alone would be expected to negatively affect the mosquito; it is only in areas where the efficacy of pyrethroids has been eroded by the development of high levels of resistance where the addition of a synergist might be needed.

There was no evidence for any difference in the performance of pyrethroid‐PBO nets from different manufacturers against highly pyrethroid‐resistant mosquitoes. We only stratified results by net type for trials that were conducted in areas of high resistance. We have not reported comparisons for DawaPlus‐PBO and Veeralin‐PBO nets in this subanalysis as there was only a single data point for these net types. Unwashed PermaNet 3.0 and Olyset Plus resulted in similar increases in mosquito mortality compared to pyrethroid‐only LLINs from the same manufacturer although this effect on mortality was not always sustained after washing ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}). A significant improvement in personal protection for unwashed pyrethroid‐PBO nets was only observed for PermaNet 3.0 ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}), but, after washing, pyrethroid‐PBO nets from both manufacturers provided greater personal protection than the equivalent pyrethroid‐only nets ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}). Results from comparisons between pyrethroid‐PBO nets from different manufacturers should be taken with great caution given the very limited number of data points available, particularly for washed nets. Further trials, where nets from different manufacturers are directly compared in the same trial are needed to address the issue of equivalence between different pyrethroid‐PBO nets.

### Certainty of the evidence {#CD012776-sec3-0028}

We appraised the certainty of the evidence using the GRADE approach ([Table 1](#CD012776-tbl-0001){ref-type="table"}, [Table 2](#CD012776-tbl-0002){ref-type="table"}, [Table 3](#CD012776-tbl-0003){ref-type="table"}, and [Table 4](#CD012776-tbl-0004){ref-type="table"}). The single RCT provides moderate‐certainty evidence that pyrethroid‐PBO nets reduce the prevalence of malaria. However, this result was obtained from a single setting ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}). The WHO recommends at least two RCTs in areas with differing levels of malaria transmission to demonstrate public health value ([WHO‐GMP 2017b](#CD012776-bbs2-0062){ref-type="ref-list"}). Hence this Cochrane Review will need to be updated once data from the large‐scale RCT of pyrethroid‐PBO nets in Uganda are available ([ISRCTN17516395](#CD012776-bbs2-0021){ref-type="ref-list"}).

The certainty of evidence from trials using entomological endpoints varied. Data from village trials were difficult to assess as there was considerable heterogeneity in the level of pyrethroid resistance, and presumably also in the resistance mechanisms, both within and between trials. Analysis of data from experimental hut trials found high‐certainty evidence for the superior performance of pyrethroid‐PBO nets in areas of high resistance but the evidence for trials conducted in other settings was of low or very low certainty.

Overall completeness and applicability of evidence {#CD012776-sec2-0012}
--------------------------------------------------

Only two published laboratory trials directly measured the impact of adding PBO to LLINs ([Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}; [Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}). All other trials included in this review compared pyrethroid‐PBO nets with the nearest equivalent pyrethroid‐only LLIN. Further changes to the net specification were often included when the manufacturers incorporated the synergist. For example, the pyrethroid‐PBO net manufactured by Vestergaard (PermaNet 3.0), contains higher levels of deltamethrin and a different denier (thickness) of yarn compared to the pyrethroid‐only equivalent, PermaNet 2.0; the pyrethroid in Olyset Plus (Sumitomo Chemical Co Ltd), is released from the yarn at a different rate than in the Olyset nets. These additional variations in the chemical or physical composition, or both, of the nets makes it difficult to directly assess the added value of the addition of PBO. Furthermore the concentration of PBO and its site of application differs markedly between nets from the different manufacturers. Two of the currently available pyrethroid‐PBO nets (PermaNet 3.0 and DawaPlus 3.0), only contain PBO on the roof of the netting, exploiting the behavioural patterns of host‐seeking mosquitoes to attempt to reach the net user by approaching from above ([Parker 2015](#CD012776-bbs2-0043){ref-type="ref-list"}), whilst the remaining pyrethroid‐PBO nets contain the synergist on all sides of the net. The amount of PBO contained within the net differs by a factor of 25‐fold. It is not known how the net manufacturers selected the doses of PBO to apply to the netting.

With the currently available data it is not possible to draw any conclusions on which strategy for producing pyrethroid‐PBO nets will prove to be the most effective under field conditions. The optimum PBO:pyrethroid ratio will likely differ depending on the level of resistance in the mosquito and the underpinning resistance mechanisms. Data from experimental hut trials suggest that the PBO component of the pyrethroid‐PBO nets is lost after repeated washing, as the enhanced mortality caused by the synergist nets is not maintained after 20 washes. As yet, no trials on the durability of pyrethroid‐PBO nets under operational conditions have been published. Encouragingly, the only clinical trial of pyrethroid‐PBO nets found that the superior protective efficacy of Olyset Plus compared to standard Olyset nets was maintained over 20 months of use ([Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}); this trial is being extended further to establish whether this effect lasts the full duration of an LLIN\'s intended 36‐month lifespan.

Most of the available data evaluated the performance of pyrethroid‐PBO LLINs against *An gambiae* s.l., with very limited data available for the second major species complex in Africa, *An funestus*, and none for other minor vector species. As different mosquito species may differ in their behaviour, and in the strength and underpinning mechanisms of pyrethroid resistance, this represents an important data gap that may have implications for practice in areas where *An gambiae* complex is not the predominant malaria vector.

Potential biases in the review process {#CD012776-sec2-0013}
--------------------------------------

As the addition of PBO to pyrethroid LLINs is only expected to enhance their performance in areas where the mosquitoes are resistant to pyrethroid insecticides, it was important to stratify the results by resistance status. To do this we used the WHO definition of resistance as mosquito populations with less than 90% mortality in a discriminating dose assay ([WHO 2016](#CD012776-bbs2-0056){ref-type="ref-list"}), and then split the resistant populations into three groups, depending on the percentage of mortality observed. Discriminating dose assays provide an estimate of the prevalence of resistance in a population but do not indicate the strength of this resistance or give any indication of the mechanism(s) underpinning this resistance. As PBO works primarily by inhibiting the metabolism of pyrethroids by cytochrome P450s, this synergist is likely to have had most impact in populations where resistance was primarily conferred by elevated P450 activity and further stratification according to resistance mechanism might have proved informative. However, in reality, characterization of resistance in mosquitoes is still primarily performed by bioassays alone and, the relevant contribution of different resistance mechanisms to the phenotype remains unknown. An exception to this is in *An funestus*, where pyrethroid resistance is almost entirely due to elevated P450 activity ([Churcher 2016](#CD012776-bbs2-0028){ref-type="ref-list"}). Unfortunately only one data set from experimental hut trials conducted where *An funestus* was the primary vector were made available to us at the time of this review.

Other examples of missing data that may have influenced the results include the absence of data on resistance status in some settings. Three experimental hut trials did not measure resistance at the time of the trial ([Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}; [N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}; [Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}). For two of these trials we used proxies for resistance; however, no proxy data were available for *An funestus* in the [Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"} trial and hence we did not include this population in the stratified analysis. Three trials did not share their data with the review authors; this included trials on nets from two of the more recent manufacturers to produce pyrethroid‐PBO nets ([N'Guessan 2016](#CD012776-bbs2-0018){ref-type="ref-list"}; [Tungu 2017](#CD012776-bbs2-0020){ref-type="ref-list"}), which precluded stratified analysis for these net types.

One of the key findings of this trial was the decline in performance of pyrethroid‐PBO nets after washing. However, as discussed above, it is not clear how the standardized washing protocol employed in experimental hut trials of LLINs reflects the actual chemical retention of active ingredients under operational use and hence the policy implications of this remain to be determined.

Agreements and disagreements with other studies or reviews {#CD012776-sec2-0014}
----------------------------------------------------------

This is the first Cochrane Review of pyrethroid‐PBO nets. An earlier meta‐analysis of experimental hut data indicated that pyrethroid‐PBO nets would have the greatest impact against mosquito populations with intermediate levels of resistance ([Churcher 2016](#CD012776-bbs2-0028){ref-type="ref-list"}). Using transmission models to convert entomological outputs into estimates of public health benefit, the trial noted that the impact of pyrethroid‐PBO nets would vary depending on mosquito species, resistance levels, malaria prevalence, and LLIN usage. The importance of taking these key parameters into account when predicting the public health impact of a switch to pyrethroid‐PBO nets has been somewhat lost in policy documents and operational guidelines which, understandably, seek to provide a simple decision rule to aid net selection. Hence, in the WHO report from the 2017 Evidence Review Group on 'Conditions for deployment of mosquito nets treated with pyrethroid and piperonyl butoxide\', it is recommended that \"National malaria control programmes and their partners should consider deployment of pyrethroid‐PBO nets in areas where pyrethroid resistance has been confirmed in the main malaria vectors\" ([WHO 2017b](#CD012776-bbs2-0058){ref-type="ref-list"}). In the technical guidelines from one of the major net distributors, the PMI, the conditions for deployment of PBO nets are \"moderate levels of pyrethroid resistance (defined as 35‐80% mortality), evidence that PBO restores pyrethroid susceptibility, and moderate to high malaria prevalence\" ([PMI 2018](#CD012776-bbs2-0044){ref-type="ref-list"}). The PMI definition of moderate resistance overlaps with our definitions of moderate and low resistance. However in our review, the best evidence for superior efficacy of pyrethroid‐PBO nets is from areas with high resistance (\< 30% mortality), and there was very little evidence for improved performance in areas with moderate or low levels of resistance. The differences between these trials may have arisen from the incorporation of a large data set of laboratory bioassays, comparing mosquito mortality with or without pre‐exposure to PBO, in the modelling trial. These laboratory bioassays rely on use of a single discriminating dose and identified multiple trials where highly resistant populations were not impacted by PBO. In the current trial, the mosquito populations included were limited to the sites in which experimental hut trials had been conducted and this may not have fully captured the full diversity of resistance mechanisms in *Anopheles* mosquitoes. This again highlights the importance of further trials on the influence of resistance mechanisms on the impact of pyrethroid‐PBO LLINs.

Authors\' conclusions {#CD012776-sec1-0007}
=====================

Implications for practiceThe findings of this review support the recent WHO policy recommendation that pyrethroid‐piperonyl butoxide (PBO) nets should be considered for deployment in areas where pyrethroid resistance has been confirmed in the main malaria vectors ([WHO‐GMP 2017a](#CD012776-bbs2-0061){ref-type="ref-list"}). Questions remain about the durability of the pyrethroid‐PBO nets. Encouragingly the single clinical trial of pyrethroid‐PBO nets did find that the protective efficacy of these nets lasted at least 21 months and this trial is being extended to see if this effect lasts the full 36 months of the intended lifespan of a long‐lasting insecticidal net (LLIN). The WHO has declared Olyset Plus as the first in class for pyrethroid‐PBO nets and as a result, pyrethroid‐PBO nets from other manufacturers will not be required to generate epidemiological evidence on their efficacy. However, a second clinical trial of pyrethroid‐PBO nets is underway in Uganda; this four‐arm trial is comparing two pyrethroid‐PBO nets (PermaNet 3.0 and Olyset Plus) with two standard LLINs (PermaNet 2.0 and Olyset).When evaluating these trials it is important to remember that the PBO is an additive to the nets, intended to increase their efficacy against pyrethroid‐resistant mosquito populations. There is no evidence to suggest that pyrethroid‐PBO nets are less effective than standard LLINs at inducing mosquito mortality under any settings. For personal protection, blood‐feeding rates are similarly decreased under all resistance scenarios when unwashed PBO nets are used, although this has not been shown for washed nets in low‐resistance or susceptible areas (low‐certainty evidence). Hence if pyrethroid‐PBO nets perform as well, or better, than standard LLINs, the decision on whether to switch to nets incorporating the synergist is largely a question of economics. With fixed budgets there is a risk that the target of universal coverage of LLINs may be harder to reach if more expensive pyrethroid‐PBO nets are deployed. Indeed, the WHO clearly states that countries should only consider deploying pyrethroid‐PBO nets in situations where coverage with standard vector‐control interventions is not reduced ([WHO‐GMP 2017c](#CD012776-bbs2-0063){ref-type="ref-list"}). Trials of the cost effectiveness of pyrethroid‐PBO nets have not yet been possible due to the uncertainties over the price differential between pyrethroid‐PBO nets and LLINs.

Implications for researchExperimental hut trials, simultaneously comparing different pyrethroid‐PBO nets in areas where mosquitoes have high levels of pyrethroid resistance levels are needed to demonstrate equivalency and inform procurement decisions, particularly given the very different approaches used to incorporate PBO into LLINs employed by the different manufacturers. The issue of durability of bioactive levels of the synergist on the nets also needs further study; current WHO protocols for measuring LLIN durability will need adjusting to utilize pyrethroid‐resistant colonies of mosquitoes so that the impact of PBO, and not just the insecticide, can be measured over the net\'s intended lifespan. The issue of the value of entomological endpoints to estimate the public health value of new types of net remains contentious ([Killeen 2018](#CD012776-bbs2-0036){ref-type="ref-list"}; [WHO‐GMP 2017c](#CD012776-bbs2-0063){ref-type="ref-list"}). Performing experimental hut trials alongside future randomized controlled trials of nets containing synergists, or other novel active ingredients, would help resolve this issue.In relation to reporting of trial results, study authors need to record the level of resistance in the local mosquito population at the time of the trial and include this when reporting the results. Data on resistance mechanisms would also be of value to understand more about how this influences the performance of pyrethroid‐PBO nets.

What\'s new {#CD012776-sec1-0013}
===========

**DateEventDescription**6 June 2019AmendedAmended Abstract, Authors\' conclusions section: from \"reduce mosquito mortality and blood feeding rates\" to \"increase mosquito mortality and reduce blood feeding rates\".
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Cochrane Library {#CD012776-sec3-0029}
================

Description:

\#1 \"piperonyl butoxide\" or PBO:ti,ab,kw (Word variations have been searched)

\#2 MeSH descriptor: \[Piperonyl Butoxide\] explode all trees

\#3 \#1 or \#2

\#4 Net\* or bednet\* or hammock\* or curtain\* or ITN\* or LLIN\* or \"Insecticide‐Treated Bednet\*\" or \"Insecticide‐Treated net\*\"

\#5 Olyset\* or PermaNet\* or Veeralin

\#6 MeSH descriptor: \[Insecticide‐Treated Bednets\] explode all trees

\#7 \#4 or \#5 or \#6

\#8 \#3 and \#7

MEDLINE (PubMed) {#CD012776-sec3-0030}
================

 Query\#1Search \"Piperonyl Butoxide\"\[Mesh\]\#2Search \"piperonyl butoxide\" or PBO Field: Title/Abstract\#3Search Olyset\* or PermaNet\* or Veeralin Field: Title/Abstract\#4Search \"Insecticide‐Treated Bednets\"\[Mesh\] Field: Title/Abstract\#5Search Nets OR bednet\* OR hammock\* OR curtain\* OR ITN\* OR LLIN\* or "Insecticide‐Treated Bednet\*" or "Insecticide‐Treated net\*" Field: Title/Abstract\#6Search ((\#5) OR \#4) OR \#3 Field: Title/Abstract\#7Search (\#2) OR \#1\#8Search (\#7) AND \#6

Embase (OVID) {#CD012776-sec3-0031}
=============

1 \"piperonyl butoxide\".mp.

2 piperonyl butoxide/

3 PBO.mp.

4 placebo/ or placebo.mp.

5 3 not 4

6 1 or 2 or 5

7 (Net\* or bednet\* or hammock\* or curtain\* or ITN\* or LLIN\* or \"Insecticide‐Treated Bednet\*\" or \"Insecticide‐Treated net\*\").mp.

8 (Olyset\* or PermaNet\* or Veeralin).mp.

9 insecticide treated net/

10 7 or 8 or 9

11 6 and 10

Web of Science^TM^ Core Collection {#CD012776-sec3-0032}
==================================

**Set** \# 8\#7 AND \#6\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years\# 7**TOPIC:** (malaria or mosquito\* or pyrethroid\* or insect\* or huts or insecticide\*)\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years\# 6\#5 AND \#4\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years\# 5**TOPIC:** (Net\* OR bednet\* OR insecticide treated net/ OR ITN\* OR LLIN\* or "Insecticide‐Treated Bednet\*" or "Insecticide‐Treated net\*") *OR***TOPIC:** (Olyset\* or PermaNet\* or Veeralin)\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years\# 4\#3 OR \#1\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years\# 3**TOPIC:** (PBO) *NOT***TOPIC:** (placebo)\
**Refined by: RESEARCH AREAS:** ( CHEMISTRY )\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years\# 2**TOPIC:** (PBO) *NOT***TOPIC:** (placebo)\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years\# 1**TOPIC:** (\"Piperonyl Butoxide\")\
Indexes=SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH Timespan=All years

CABI: CAB Abstracts® {#CD012776-sec3-0033}
====================

**Set** \# 3\#2 AND \#1\
Indexes=CAB Abstracts Timespan=All years\# 2**TOPIC:** (Net\* OR bednet\* OR hammock\* OR curtain\* OR ITN\* OR LLIN\* or "Insecticide‐Treated Bednet\*" or "Insecticide‐Treated net\*") *OR***TOPIC:** (Olyset\* or PermaNet\* or Veeralin)\
Indexes=CAB Abstracts Timespan=All years\# 1**TOPIC:** (PBO or \"Piperonyl Butoxide\")\
Indexes=CAB Abstracts Timespan=All years

ClinicalTrials.gov and WHO ICTRP {#CD012776-sec3-0034}
================================

piperonyl butoxide and malaria

**Table 2.1** Trial characteristics of the included cone bioassays

**TrialIDTrialnameMosquito species (strain/origin)Resistance levelResistance statusMosquito ageBlood‐fed statusInterventionWashingMeasured outcome; mosquito mortality**          

**Table 2.2** Trial characteristics of the included ball bioassays

**TrialIDTrialnameMosquito species (strain/origin)Resistance levelResistance statusMosquito ageBlood‐fed statusInterventionWashingMeasured outcome; mosquito mortality**          

**Table 2.3** Trial characteristics of the included tunnel tests

**TrialIDTrialnameMosquito species (strain/origin)Resistance levelResistance statusMosquito ageBlood‐fed statusInterventionWashingMeasured outcomeKDMBFNPTN**             

Abbreviations: KD: knock‐down; M: mortality; BF; blood feeding; NPTN: not passed though net.

**Table 2.4** Trial characteristics of the included experimental hut trials

**TrialIDTrialnameTriallocationMosquito species (strain/origin)Resistance levelResistance statusTrialstart/end dateInterventionNet washedNet holedMeasured outcomeMBFDE**              

Abbreviations: M: mortality; BF; blood feeding; D: deterrence; E: exophily.

**Table 2.5** Trial characteristics of the included village trials

**TrialIDTrialnameTriallocationMosquito species (strain/origin)Resistance levelResistance statusTrialstart/end dateInterventionNet washedNet holedMeasured outcomeMBFSRMDPRPPCMC**                 

Abbreviations: M: mortality; BF: blood feeding; SR: sporozoite rate; MD: mosquito density; PR: parity rate; PP: parasite presence; CMC: clinical malaria confirmation.

**Table 3.1** Data extracted from laboratory bioassays.

**TrialIDTrialnameNet typeNet washedMosquito speciesResistance levelResistance statusTotal mosquitoDeadMosquito mortality (%)BFBF (%)NPTNNPTN (%)**              

Abbreviations: BF: blood feeding; NPTN: not passed through net.

**Table 3.2** Data extracted from experimental hut trials

**TrialIDTrialnameNet typeNet washedNet holedMosquito speciesResistance levelResistance statusTotal mosquitoesDeadMosquito mortality (%)BFBF (%)BFINumber of mosquitoes deterredDeterrence (%)Exit trapExophily (%)Total number of people (N)**                   

Abbreviations: BF: blood feeding; BFI: blood feeding inhibition; N: number of people.

**Table 3.3** Data extracted from village trials

**TrialIDTrialnameNet typeNet washedNet holedMosquito speciesResistance levelResistance statusTotal mosquitoesDeadMosquito mortality (%)BFBF (%)BFISporozoite (%)Mosquito density (%)Parity (%)Total number of people (N)PP**\
**(%)CMC**\
**(%)**                    

Abbreviations: BF: blood feeding; PP: parasite prevalence; CMC: clinical malaria confirmation; N: number of people.

**Table 4.1** 'Risk of bias\' assessment for laboratory bioassays

**TrialIDTrialnameComparability of mosquitoes in LLIN and LLIN + PBO groupsObservers blindedIncomplete outcome dataRaw data reported for LLIN and LLIN + PBO groupsAuthors\' conflicting interest**       

Abbreviations: LLIN: long‐lasting insecticidal nets; PBO: piperonyl butoxide.

**Table 4.2** 'Risk of bias\' assessment for experimental hut trials

**TrialIDTrialnameComparability of mosquitoes in LLIN and LLIN+PBO groupsCollectors blindedSleepers blindedSleeper biasTreatment allocationTreatment rotationStandardized hut designHut cleaning between treatmentsIncomplete outcome dataRaw data reported for both treatment groupsAuthors\' conflicting interest**             

**Table 4.3** 'Risk of bias\' assessment for village trials

**TrialIDTrialnameComparability of mosquitoes in LLIN and LLIN + PBO householdsCollectors blindedHousehold blindedAllocation of treatmentsIncomplete outcome dataRaw data reported for both groupsAuthors\' conflicting interest**         

Abbreviations: LLIN: long‐lasting insecticidal nets; PBO: piperonyl butoxide.

**Risk of bias componentLowUnclearHigh**Mosquito group comparabilitySame strain or population of mosquitoesNo or unclear information reportedDifferent strain or population of mosquitoesObservers blindedOutcomes assessed blindedNo or unclear information reported\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low risk.Outcomes assessed not blinded, and this is likely to influence the results\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low risk.Incomplete outcome data addressedNo or low missing data, reason for missing data is unlikely to be related to the true outcomeNo or unclear information reportedHigh missing data, reason for missing data is likely to be related to the true outcomeRaw data reportedRaw data reportedNo or unclear information reportedRaw data not reportedConflicting interestsNo conflict of interest is statedNo or unclear information reportedConflict of interest stated

**Risk of bias componentLowUnclearHigh**Mosquito group comparabilityHuts accessible to the same mosquito populationNo or unclear information reportedHuts not accessible to the same mosquito populationCollectors blindedOutcomes assessed blindedNo or unclear information reported\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low risk.Outcomes assessed not blinded, and this is likely to influence the results\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low risk.Sleepers blindedOutcomes assessed blindedNo or unclear information reported\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low riskOutcomes assessed not blinded, and this is likely to influence the results.\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low riskSleeper biasSleepers were rotated between huts using a Latin square designNo or unclear information reportedSleepers not rotated between hutsTreatment allocationTreatments randomized\
Treatments not‐randomized however equal attractiveness demonstratedNo or unclear information reportedTreatments not randomized, and equal attractiveness not demonstratedTreatment rotationTreatments rotated through huts using a Latin square designNo or unclear information reportedTreatments not rotatedStandardized hut designHuts of West‐ or East‐African designNo or unclear information reportedHuts of non‐standardized designCleaningHuts cleaned between treatmentsNo or unclear information reportedHuts not cleaned between treatmentsIncomplete outcome data addressedNo or low missing data, reason for missing data is unlikely to be related to the true outcomeNo or unclear information reportedHigh missing data, reason for missing data is likely to be related to the true outcomeRaw data reportedRaw data reportedNo or unclear information reportedRaw data not reportedConflicting interestsNo conflict of interest is statedNo or unclear information reportedConflict of interest stated

**Risk of bias componentLowUnclearHigh**Recruitment biasNo participants recruited after clusters randomizedNo or unclear information reported\
Recruitment bias not applicable to trial design as it is related to human participantsParicipants recruited to trial after clusters randomizedMosquito group comparabilityMosquito populations comparableNo or unclear information reportedMosquito populations comparableCollectors blindedOutcomes assessed blindedNo or unclear information reported\
Outcomes assessed not blinded, but this is unlikely to influence the resultsOutcomes assessed not blinded, and this is likely to influence the resultsHousehold blindedOutcomes assessed blindedNo or unclear information reported\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low risk.Outcomes assessed not blinded, and this is likely to influence the results\
If outcomes assessed were not blinded, but this is unlikely to influence the results, we will judge this to be low risk.Treatment allocationTreatments randomizedNo or unclear information reportedTreatments not randomizedAllocation concealmentAllocation concealment procedures were adhered to.No or unclear information reported\
Allocation concealment procedures where not adhered to, however this is unlikely to affect the results.Allocation procedures were not adhered to and this is likely to have affected the results.Incomplete outcome data addressedNo or low missing data, reason for missing data is unlikely to be related to the true outcomeNo or unclear information reportedHigh missing data, reason for missing data is likely to be related to the true outcomeRaw data reportedRaw data reportedNo or unclear information reportedRaw data not reportedClusters lost to follow‐upNo complete clusters lost from trialNo or unclear information as to whether clusters were lost from trialAt least one cluster lost from trialSelective reportingNo selective reporting, all measured outcomes reported in resultsNo or unclear information on whether all measured outcomes were reported in resultsSelective reporting; not all measured outcomes were reported in resultsCorrect statistical methods; adjusted for clusteringClustering was taken into account and statistical methods adjusted for clusteringNo or unclear information as to whether clustering was taken into account for statistical methods.Trial did not take clustering into account for statistical methodsConflicting interestsNo conflict of interest is statedNo or unclear information reportedConflict of interest stated

###### 

Pyrethroid‐PBO nets versus LLINs: laboratory bioassay (cone trials)

  Outcome or subgroup title                                     No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Mosquito mortality](#CD012776-fig-00101){ref-type="fig"}   2                558                   Risk Ratio (M‐H, Fixed, 95% CI)   6.06 \[4.15, 8.84\]

![Comparison 1 Pyrethroid‐PBO nets versus LLINs: laboratory bioassay (cone trials), Outcome 1 Mosquito mortality.](nCD012776-CMP-001-01){#CD012776-fig-00101}

###### 

Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials

  Outcome or subgroup title                                                                                       No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Mosquito mortality (pooled) hut/night](#CD012776-fig-00201){ref-type="fig"}                                  8                14334                 Risk Ratio (M‐H, Random, 95% CI)   1.36 \[1.20, 1.54\]
  1.1 Unwashed                                                                                                    8                7742                  Risk Ratio (M‐H, Random, 95% CI)   1.54 \[1.21, 1.96\]
  1.2 Washed                                                                                                      7                6592                  Risk Ratio (M‐H, Random, 95% CI)   1.14 \[1.00, 1.31\]
  [2 Mosquito blood‐feeding success (pooled) hut/night](#CD012776-fig-00202){ref-type="fig"}                      7                11070                 Risk Ratio (M‐H, Random, 95% CI)   0.76 \[0.67, 0.88\]
  2.1 Unwashed                                                                                                    7                6355                  Risk Ratio (M‐H, Random, 95% CI)   0.66 \[0.54, 0.79\]
  2.2 Washed                                                                                                      6                4715                  Risk Ratio (M‐H, Random, 95% CI)   0.91 \[0.78, 1.06\]
  [3 Mosquito exophily (pooled) hut/night](#CD012776-fig-00203){ref-type="fig"}                                   8                11933                 Risk Ratio (M‐H, Random, 95% CI)   0.99 \[0.94, 1.06\]
  3.1 Unwashed                                                                                                    8                6793                  Risk Ratio (M‐H, Random, 95% CI)   1.01 \[0.91, 1.12\]
  3.2 Washed                                                                                                      7                5140                  Risk Ratio (M‐H, Random, 95% CI)   0.98 \[0.92, 1.04\]
  [4 Mosquito mortality (high resistance) hut/night](#CD012776-fig-00204){ref-type="fig"}                         5                7997                  Risk Ratio (M‐H, Random, 95% CI)   1.58 \[1.34, 1.86\]
  4.1 Unwashed                                                                                                    5                4896                  Risk Ratio (M‐H, Random, 95% CI)   1.84 \[1.60, 2.11\]
  4.2 Washed                                                                                                      4                3101                  Risk Ratio (M‐H, Random, 95% CI)   1.20 \[0.88, 1.63\]
  [5 Mosquito blood‐feeding success (high resistance) hut/night](#CD012776-fig-00205){ref-type="fig"}             4                7134                  Risk Ratio (M‐H, Random, 95% CI)   0.66 \[0.57, 0.76\]
  5.1 Unwashed                                                                                                    4                4458                  Risk Ratio (M‐H, Random, 95% CI)   0.60 \[0.50, 0.71\]
  5.2 Washed                                                                                                      3                2676                  Risk Ratio (M‐H, Random, 95% CI)   0.81 \[0.72, 0.92\]
  [6 Mosquito mortality (moderate resistance) hut/night](#CD012776-fig-00206){ref-type="fig"}                     1                493                   Risk Ratio (M‐H, Fixed, 95% CI)    1.12 \[0.90, 1.40\]
  6.1 Unwashed                                                                                                    1                217                   Risk Ratio (M‐H, Fixed, 95% CI)    1.16 \[0.88, 1.54\]
  6.2 Washed                                                                                                      1                276                   Risk Ratio (M‐H, Fixed, 95% CI)    1.07 \[0.74, 1.54\]
  [7 Mosquito blood‐feeding success (moderate resistance) hut/night](#CD012776-fig-00207){ref-type="fig"}         1                499                   Risk Ratio (M‐H, Random, 95% CI)   0.90 \[0.76, 1.06\]
  7.1 Unwashed                                                                                                    1                217                   Risk Ratio (M‐H, Random, 95% CI)   0.87 \[0.67, 1.13\]
  7.2 Washed                                                                                                      1                282                   Risk Ratio (M‐H, Random, 95% CI)   0.91 \[0.74, 1.13\]
  [8 Mosquito mortality (low resistance) hut/night](#CD012776-fig-00208){ref-type="fig"}                          1                1224                  Risk Ratio (M‐H, Random, 95% CI)   1.13 \[1.02, 1.25\]
  8.1 Unwashed                                                                                                    1                577                   Risk Ratio (M‐H, Random, 95% CI)   1.10 \[1.05, 1.16\]
  8.2 Washed                                                                                                      1                647                   Risk Ratio (M‐H, Random, 95% CI)   1.16 \[0.83, 1.63\]
  [9 Mosquito blood‐feeding success (low resistance) hut/night](#CD012776-fig-00209){ref-type="fig"}              1                1224                  Risk Ratio (M‐H, Random, 95% CI)   1.43 \[0.85, 2.41\]
  9.1 Unwashed                                                                                                    1                577                   Risk Ratio (M‐H, Random, 95% CI)   0.67 \[0.06, 7.37\]
  9.2 Washed                                                                                                      1                647                   Risk Ratio (M‐H, Random, 95% CI)   1.50 \[0.89, 2.54\]
  [10 Mosquito mortality (susceptible) hut/night](#CD012776-fig-00210){ref-type="fig"}                            2                1916                  Risk Ratio (M‐H, Random, 95% CI)   1.05 \[0.96, 1.15\]
  10.1 Unwashed                                                                                                   2                948                   Risk Ratio (M‐H, Random, 95% CI)   1.20 \[0.64, 2.26\]
  10.2 Washed                                                                                                     2                968                   Risk Ratio (M‐H, Random, 95% CI)   1.07 \[0.92, 1.25\]
  [11 Mosquito blood‐feeding success (susceptible) hut/night](#CD012776-fig-00211){ref-type="fig"}                2                1916                  Risk Ratio (M‐H, Random, 95% CI)   0.87 \[0.40, 1.89\]
  11.1 Unwashed                                                                                                   2                948                   Risk Ratio (M‐H, Random, 95% CI)   0.52 \[0.12, 2.22\]
  11.2 Washed                                                                                                     2                968                   Risk Ratio (M‐H, Random, 95% CI)   1.25 \[0.82, 1.91\]
  [12 Mosquito mortality (high resistance/Permanet) hut/night](#CD012776-fig-00212){ref-type="fig"}               3                2806                  Risk Ratio (M‐H, Random, 95% CI)   1.59 \[1.26, 2.01\]
  12.1 Not Washed                                                                                                 3                1877                  Risk Ratio (M‐H, Random, 95% CI)   1.81 \[1.56, 2.10\]
  12.2 Washed                                                                                                     2                929                   Risk Ratio (M‐H, Random, 95% CI)   1.18 \[0.61, 2.28\]
  [13 Mosquito blood‐feeding success (high resistance/Permanet) hut/night](#CD012776-fig-00213){ref-type="fig"}   2                1943                  Risk Ratio (M‐H, Random, 95% CI)   0.58 \[0.45, 0.76\]
  13.1 Unwashed                                                                                                   2                1439                  Risk Ratio (M‐H, Random, 95% CI)   0.53 \[0.40, 0.69\]
  13.2 Washed                                                                                                     1                504                   Risk Ratio (M‐H, Random, 95% CI)   0.76 \[0.61, 0.93\]
  [14 Mosquito mortality (high resistance/Olyset) hut/night](#CD012776-fig-00214){ref-type="fig"}                 2                1410                  Risk Ratio (M‐H, Random, 95% CI)   1.73 \[1.51, 1.97\]
  14.1 Unwashed                                                                                                   2                1257                  Risk Ratio (M‐H, Random, 95% CI)   1.72 \[1.48, 1.99\]
  14.2 Washed                                                                                                     1                153                   Risk Ratio (M‐H, Random, 95% CI)   1.81 \[1.25, 2.61\]
  [15 Mosquito blood‐feeding success (high resistance/Olyset) hut/night](#CD012776-fig-00215){ref-type="fig"}     2                1470                  Risk Ratio (M‐H, Random, 95% CI)   0.63 \[0.40, 0.98\]
  15.1 Unwashed                                                                                                   2                1257                  Risk Ratio (M‐H, Random, 95% CI)   0.67 \[0.38, 1.18\]
  15.2 Washed                                                                                                     1                213                   Risk Ratio (M‐H, Random, 95% CI)   0.50 \[0.27, 0.93\]

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 1 Mosquito mortality (pooled) hut/night.](nCD012776-CMP-002-01){#CD012776-fig-00201}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 2 Mosquito blood‐feeding success (pooled) hut/night.](nCD012776-CMP-002-02){#CD012776-fig-00202}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 3 Mosquito exophily (pooled) hut/night.](nCD012776-CMP-002-03){#CD012776-fig-00203}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 4 Mosquito mortality (high resistance) hut/night.](nCD012776-CMP-002-04){#CD012776-fig-00204}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 5 Mosquito blood‐feeding success (high resistance) hut/night.](nCD012776-CMP-002-05){#CD012776-fig-00205}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 6 Mosquito mortality (moderate resistance) hut/night.](nCD012776-CMP-002-06){#CD012776-fig-00206}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 7 Mosquito blood‐feeding success (moderate resistance) hut/night.](nCD012776-CMP-002-07){#CD012776-fig-00207}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 8 Mosquito mortality (low resistance) hut/night.](nCD012776-CMP-002-08){#CD012776-fig-00208}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 9 Mosquito blood‐feeding success (low resistance) hut/night.](nCD012776-CMP-002-09){#CD012776-fig-00209}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 10 Mosquito mortality (susceptible) hut/night.](nCD012776-CMP-002-10){#CD012776-fig-00210}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 11 Mosquito blood‐feeding success (susceptible) hut/night.](nCD012776-CMP-002-11){#CD012776-fig-00211}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 12 Mosquito mortality (high resistance/Permanet) hut/night.](nCD012776-CMP-002-12){#CD012776-fig-00212}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 13 Mosquito blood‐feeding success (high resistance/Permanet) hut/night.](nCD012776-CMP-002-13){#CD012776-fig-00213}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 14 Mosquito mortality (high resistance/Olyset) hut/night.](nCD012776-CMP-002-14){#CD012776-fig-00214}

![Comparison 2 Commercial pyrethroid‐PBO nets versus commercial LLINs: hut trials, Outcome 15 Mosquito blood‐feeding success (high resistance/Olyset) hut/night.](nCD012776-CMP-002-15){#CD012776-fig-00215}

###### 

Commercial pyrethroid‐PBO nets versus commercial LLINs: village trials

  Outcome or subgroup title                                                                  No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ---------------------
  [1 Prevalence of malaria](#CD012776-fig-00301){ref-type="fig"}                             1                                      Odds Ratio (Fixed, 95% CI)         0.40 \[0.20, 0.80\]
  [2 Mosquito sporozoite‐positive (adjusted ICC 0.1)](#CD012776-fig-00302){ref-type="fig"}   4                424                   Risk Ratio (M‐H, Random, 95% CI)   0.82 \[0.24, 2.75\]
  [3 Mosquito parous (adjusted ICC 0.1)](#CD012776-fig-00303){ref-type="fig"}                3                220                   Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.82, 1.13\]

![Comparison 3 Commercial pyrethroid‐PBO nets versus commercial LLINs: village trials, Outcome 1 Prevalence of malaria.](nCD012776-CMP-003-01){#CD012776-fig-00301}

![Comparison 3 Commercial pyrethroid‐PBO nets versus commercial LLINs: village trials, Outcome 2 Mosquito sporozoite‐positive (adjusted ICC 0.1).](nCD012776-CMP-003-02){#CD012776-fig-00302}

![Comparison 3 Commercial pyrethroid‐PBO nets versus commercial LLINs: village trials, Outcome 3 Mosquito parous (adjusted ICC 0.1).](nCD012776-CMP-003-03){#CD012776-fig-00303}

Characteristics of included studies \[author‐defined order\] {#CD012776-sec2-0024}
============================================================

[Awolola 2014](#CD012776-bbs2-0001){ref-type="ref-list"}MethodsVillage trialParticipantsIlara ‐ *An gambiae* (100% S‐form)  Irolu ‐ 95% *An gambiae* (100% S‐form), 4.5% *An arabiensis*  Ijesa ‐ 98.1% *An gambiae* (80% S‐form, 19% M‐form), *An arabiensis* (1.6%)InterventionsControl: LLIN, PermaNet 2.0\
Intervention: LLIN, PermaNet 3.0OutcomesMosquito mortality, blood feeding, sporozoite rate, mosquito density, parity rateMosquito resistance statusIlara ‐ resistant ‐ low (deltamethrin, 72.5% mortality, N = 120)  Irolu ‐ resistant ‐ low (deltamethrin, 62.5% mortality, N = 120)  Ijesa ‐ resistant ‐ low (deltamethrin, 66.7% mortality, N = 120)Net treatmentNets unholed and unwashedLocation(s)Ilara, Nigeria ‐ untreated net  Irolu, Nigeria ‐ PermaNet 2.0  Ijesa, Nigera ‐ PermaNet 3.0NotesTrial conducted: March 2012‐March 2013***Risk of bias*BiasAuthors\' judgementSupport for judgement**Recruitment biasLow riskRecruiment bias is related to human participants and so not applicable to this study.Were the mosquitoes in LLIN and LLIN + PBO groups comparableUnclear riskMosquito species composition varied slightly pre‐ and post‐trial between the treatment villages. However, resistance level was the same.Collectors blindedHigh riskNot stated if collectors where blinded, therefore judged as high risk as this is likely to impact searching effort.Household blindedLow riskUnclear if households were blinded -- not stated in the publication. We judged this as low as this is unlikely to affect the outcome.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskVillages were randomly assigned to treatment armsAllocation concealment (selection bias)Low riskAllocation concealment procedures were not adhered to, however this is unlikely to affect the resultsWere incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reported.Clusters lost to follow‐upLow riskNo clusters lost to follow‐upSelective reporting (reporting bias)Low riskAll measured outcomes appear to be reportedCorrect statistical methods; adjusted for clusteringHigh riskStudy did not take clustering into account for statistical methodsTrial authors\' conflicting interestLow riskThe trial authors declared no conflicting interests, however the study was funded by Vestergaard (net manufacturers). Views and findings in the publication are stated to be those of the trial authors[Bayili 2017](#CD012776-bbs2-0002){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An coluzzii*InterventionsControl: LLIN, DawaPlus 2.0\
Intervention: LLIN: DawaPlus 3.0, DawaPlus 4.0OutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito resistance statusResistant ‐ high (6% mortality, N = 98)Net treatmentNets holed, nets unwashed and washed (x 20)Location(s)Vallée du Kou, Burkina FasoNotesTrial conducted: August 2016‐October 2016***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskThe hut trial was conducted in the same area, therefore characteristics are similarCollectors blindedUnclear riskPaper does not state if collectors were blindedSleepers blindedUnclear riskPaper does not state if sleepers were blindedSleeper biasLow riskSleepers were rotated between hut following a Latin square designTreatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were not randomly allocated to huts however the trial completed a full rotation through the hutsTreatment rotationLow riskTreatments were rotated between hut following a Latin square design + 2 weeksStandardized hut designLow riskHut were built previously using standard West‐African designHut cleaning between treatmentsUnclear riskDoes not state if huts were cleaned between treatmentsWere incomplete outcome data adequately addressedLow riskThere were no incomplete dataWere the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data was reportedTrial authors\' conflicting interestLow riskThe authors declare no conflicting interest in the WHOPES report.[Cisse 2017](#CD012776-bbs2-0003){ref-type="ref-list"}MethodsVillage trialParticipants*An gambiae* s. s.InterventionsControl: LLIN, Olyset Net & PermaNet 2.0\
Intervention: LLIN, Olyset Plus & PermaNet 3.0OutcomesSporozoite rate, mosquito density, parity rateMosquito resistance statusOlyset Net villages ‐ resistance ‐ high (1% mortality, N = 305)  Olyset Plus villages ‐ resistance ‐ high (2% mortality, N = 411)  PermaNet 2.0 villages ‐ resistance ‐ high (29% mortality, N = 410)  PermaNet 3.0 villages ‐ resistance ‐ moderate (38% mortality, N = 408)Net treatmentNets unholed and unwashedLocation(s)Sikasso region, Mali\
PermaNet 2.0 villages ‐ Beko East, Dalabani, Berila, Dierila  PermaNet 3.0 villages ‐ Beko West, Farabacoura East, Kola Djokada, Tieblembougou  Olyset Net villages ‐ Karako, Geleba 2, Toula East, Toula West  Olyset Plus villages ‐ Dialake, Farabacoura West, Deneklin, FaradjeleNotesTrial conducted: January 2014‐January 2015***Risk of bias*BiasAuthors\' judgementSupport for judgement**Recruitment biasLow riskRecruiment bias is related to human participants and so not applicable to this studyWere the mosquitoes in LLIN and LLIN + PBO groups comparableUnclear riskMosquito species composition constant between villages, however resistance level varies slightly.Collectors blindedHigh riskNot stated if collectors where blinded therefore judged as high risk as this is likely to affect searching effort.Household blindedLow riskUnclear if households were blinded -- not stated in the publication. We judged this as low as this is unlikely to affect the outcomeTreatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskVillages were randomly assigned to treatment arms.Allocation concealment (selection bias)Low riskAllocation concealment procedures were not adhered to, however this is unlikely to affect the results.Were incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reportedClusters lost to follow‐upLow riskNo clusters lost to follow‐upSelective reporting (reporting bias)Low riskAll measured outcomes appear to be reported.Correct statistical methods; adjusted for clusteringHigh riskStudy did not take clustering into account for statistical methods.Trial authors\' conflicting interestLow riskThe trial authors have no competing interests[Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"}MethodsExperimental hut trialParticipantsVallée du Kou, Burkina Faso ‐ 100% *An gambiae*: M‐form (15%), S‐form (85%)\
Malanville, Benin ‐ 95% *An gambiae*: M‐form (100%), 5% *An arabiensis*\
Pitoa, Cameroon ‐ 5% *An gambiae*: S‐form (100%), 95% *An arabiensis*InterventionsControl: LLIN, PermaNet 2.0\
Intervention: LLIN, PermaNet 3.0OutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito resistance statusVallée du Kou, Burkina Faso ‐ resistant -- high (deltamethrin, 23% mortality, N = 100)\
Malanville, Benin ‐ resistant -- low (deltamethrin, 85% mortality, N = 100)\
Pitoa, Cameroon ‐ resistant -- low (deltamethrin, 70% mortality, N = 100)Net treatmentNets holed, nets unwashed and washed (x 20)Location(s)Vallée du Kou, Burkina Faso\
Malanville, Benin\
Pitoa, CameroonNotesTrial conducted:\
Vallée du Kou, Burkina Faso ‐ September 2007 to November 2007\
Malanville, Benin ‐ July 2008 to September 2008\
Pitoa, Cameroon ‐ July 2008 to September 2008***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskHuts situated in the same area -- mosquito characteristics will be the sameCollectors blindedUnclear riskUnclear if collectors blinded -- not stated in publicationSleepers blindedUnclear riskUnclear if sleeper blinded -- not stated in publicationSleeper biasLow riskSleepers were rotated between huts using a Latin square design.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were randomly allocated to huts.Treatment rotationLow riskTreatments were rotated between huts using a Latin square designStandardized hut designLow riskHuts were built in a standard West‐African design.Hut cleaning between treatmentsUnclear riskUnclear if huts were cleaned between treatments -- not stated in publicationWere incomplete outcome data adequately addressedLow riskThere were no incomplete outcome dataWere the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reported.Trial authors\' conflicting interestLow riskThe trial authors have no competing interests[Darriet 2011](#CD012776-bbs2-0005){ref-type="ref-list"}MethodsCone assayParticipants2‐5‐day‐old female unfed *An gambiae* VKPR laboratory strain (originated from Kou Valley, Burkina‐Faso and maintained for \> 15 years under laboratory conditions)InterventionsControl: ITN treated with deltamethrin (25 mg/m^2^)\
Intervention: ITN treated with deltamethrin (25 mg/m^2^) & PBO (222.24 mg/m^2^)OutcomesMosquito mortalityMosquito resistance statusResistant colony, unclassifiedNet treatmentNets unwashedLocation(s)N/ANotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskSame mosquito strain used for all treatment groupsWere the study observers blinded to the allocated interventionUnclear riskUnclear if observers were blinded -- not stated in the publication, but also not common practice. We judged this as low as this is unlikely to impact on the outcome.Were incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskThe resistance status of the *Anopheles gambiae* VKPR lab strain is not stated in the publication.Trial authors\' conflicting interestLow riskThe trial authors do not state any conflicting interests[Darriet 2013](#CD012776-bbs2-0006){ref-type="ref-list"}MethodsCone assayParticipants2‐5‐day‐old female unfed *An gambia*e VKPR laboratory strain (originated from Kou Valley, Burkina‐Faso and maintained for \> 15 years under laboratory conditions)InterventionsControl: ITN treated with deltamethrin (25 mg/m^2^)\
Intervention: ITN treated with deltamethrin (25 mg/m^2^) & PBO (222.24 mg/m^2^)OutcomesMosquito mortalityMosquito resistance statusResistant colony, unclassifiedNet treatmentN/ALocation(s)N/ANotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskSame mosquito strain used for all treatment groupsWere the study observers blinded to the allocated interventionUnclear riskUnclear if observers were blinded -- not stated in the publication, but also not common practice. We judged this as low as this is unlikely to impact on the outcome.Were incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskThe resistance status of the *Anopheles gambiae* VKPR lab strain is not stated in the publication.Trial authors\' conflicting interestLow riskThe trial authors do not state any conflicting interests.[Koudou 2011](#CD012776-bbs2-0007){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An gambiae* s.s.InterventionsControl: LLIN, PermaNet 2.0\
Intervention: LLIN, PermaNet 3.0OutcomesMosquito mortality, deterrence, exophilyMosquito resistance statusResistant ‐ high (deltamethrin, 10.6% mortality, N = 80 min)Net treatmentNets not holed, nets unwashed and washed (x 20)Location(s)Yaokoffikro, Côte d\'IvoireNotesTrial conducted: April 2009‐July 2009***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskHuts situated in the same area -- mosquito characteristics will be the sameCollectors blindedUnclear riskUnclear if collectors blinded -- not stated in publicationSleepers blindedUnclear riskUnclear if sleeper blinded -- not stated in publicationSleeper biasLow riskSleepers were rotated between huts using a Latin square designTreatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were not randomly allocated to the huts.\
However, results from trials performed before this trial showed no significant difference in attractiveness of the different hutsTreatment rotationLow riskTreatments were rotated between huts using a Latin square designStandardized hut designLow riskHuts were built in a standard West‐African designHut cleaning between treatmentsLow riskAll huts were cleaned between treatmentsWere incomplete outcome data adequately addressedLow riskThere were no incomplete dataWere the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reportedTrial authors\' conflicting interestLow riskThe trial authors declared there were no conflicting interests.[Moore 2016](#CD012776-bbs2-0008){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An arabiensis* (100%), *An funestus* group (95% s.s.)InterventionsControl: LLIN, MAGNet LN\
Intervention: LLIN, Veeralin LNOutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito resistance status*An arabiensis* ‐ susceptible (alphacypermethrin, 100% mortality, N = 97)\
*An funestus* ‐ unclassifiedNet treatmentNets holed, nets unwashed and washed (x 20)Location(s)Ifakara, TanzaniaNotesAlthough additional data provided showed resistance to deltamethrin and permethrin in *An gambaie s.l.****Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskThe hut trial was conducted in the same area, therefore characteristics are similarCollectors blindedUnclear riskPaper does not state if collectors were blinded.Sleepers blindedUnclear riskPaper does not state if sleepers were blinded.Sleeper biasLow riskSleepers were rotated between hut following a Latin square design.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were not randomly allocated to huts however the trial completed a full rotation through the huts.Treatment rotationLow riskTreatments were rotated between hut following a Latin square design.Standardized hut designLow riskThe study used the standard design of the Ifakara experimental huts.Hut cleaning between treatmentsUnclear riskThe paper does not state if huts were cleared between treatments.Were incomplete outcome data adequately addressedLow riskNo incomplete outcome dataWere the raw data reported for LLIN and LLIN + PBO groupsLow riskNo missing outcome dataTrial authors\' conflicting interestLow riskThe trial authors declared they received prescribed standard fees from Vestergaard Frandsen for evaluating their pesticide products, however this is standard practice.[Mzilahowa 2014](#CD012776-bbs2-0009){ref-type="ref-list"}MethodsVillage trialParticipants*An gambiae* s. l., *An funestus g*roupInterventionsControl: LLIN, Olyset Net & PermaNet 2.0\
Intervention: LLIN, Olyset Plus & PermaNet 3.0OutcomesMosquito density, parity rateMosquito resistance status*An funestus* (Balaka district)\
Permethrin ‐ resistant ‐ moderate (55.5% mortality, N = unknown)\
Deltamethrin ‐ resistant ‐ high (14.9% mortality, N = unknown)\
*An gambiae (*Balaka district)\
Permethrin ‐ resistant ‐ low (84.4% mortality, N = unknown)\
(Machinga district)\
Deltamethrin ‐ resistant ‐ moderate (54.5% mortality, N = unknown)Net treatmentNets unholed and unwashedLocation(s)Balaka district, Malawi (12 villages)NotesTrial conducted: December 2012‐June 2014***Risk of bias*BiasAuthors\' judgementSupport for judgement**Recruitment biasLow riskRecruiment bias is related to human participants and so not applicable to this study.Were the mosquitoes in LLIN and LLIN + PBO groups comparableHigh riskMosquito species composition and resistance status are not recorded per village. Village names are not provided in study, instead villages are grouped by treatment type.Collectors blindedHigh riskNot stated if collectors were blinded, therefore judged as high risk as this is likely to affect searching effort.Household blindedLow riskUnclear if households were blinded -- not stated in the publication. We judged this as low as this is unlikely to affect the outcome.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskVillages were randomly assigned to treatment arms.Allocation concealment (selection bias)Low riskAllocation concealment procedures were not adhered to, however this is unlikely to affect the results.Were incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reportedClusters lost to follow‐upLow riskNo clusters lost to follow‐up.Selective reporting (reporting bias)Low riskAll measured outcomes appear to be reportedCorrect statistical methods; adjusted for clusteringHigh riskStudy did not take clustering into account when performing statistical methodsTrial authors\' conflicting interestUnclear riskThere is no information on trial authors\' possible conflicting interests provided.[N\'Guessan 2010](#CD012776-bbs2-0010){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An gambiae*InterventionsControl: LLIN, PermaNet 2.0\
Intervention: LLIN, PermaNet 3.0OutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito resistance statusProxy data. Adjara, Benin: resistant ‐ moderate (deltamethrin, 50% mortality, N = 56) ([Aïzoun 2013](#CD012776-bbs2-0025){ref-type="ref-list"})Net treatmentNets holed, nets unwashed and washed (x 20)Location(s)Akron, BeninNotesTrial conducted: October 2008‐January 2009***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskHuts situated in the same area -- mosquito characteristics will be the sameCollectors blindedUnclear riskUnclear if collectors blinded -- not stated in publicationSleepers blindedUnclear riskUnclear if sleeper blinded -- not stated in publicationSleeper biasLow riskSleepers were rotated between huts using a Latin square designTreatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were randomly allocated to hutsTreatment rotationLow riskTreatments were rotated between huts using a Latin square design.Standardized hut designLow riskHuts were built in a standard West‐African design.Hut cleaning between treatmentsLow riskAll huts were cleaned between treatments.Were incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reportedTrial authors\' conflicting interestUnclear riskThe trial was sponsored by Vestergaard (net manufacturers), who also commented on the manuscript[Pennetier 2013](#CD012776-bbs2-0011){ref-type="ref-list"}MethodsExperimental hut trialParticipants95% *An gambiae*: M‐form (100%), 5% *An arabiensis* ([Corbel 2010](#CD012776-bbs2-0004){ref-type="ref-list"})InterventionsControl: LLIN, Olyset Net\
Intervention: LLIN, Olyset PlusOutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito resistance statusProxy data. Resistant ‐ high (permethrin, 22% mortality, N = 100) ([Djègbè 2011](#CD012776-bbs2-0030){ref-type="ref-list"})Net treatmentNets holed, nets unwashed and washed (x 20)Location(s)Malanville, BeninNotesTrial conducted: September 2011‐December 2011***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskHuts situated in the same area -- mosquito characteristics will be the sameCollectors blindedUnclear riskUnclear if collectors blinded -- not stated in publicationSleepers blindedUnclear riskUnclear if sleeper blinded -- not stated in publicationSleeper biasLow riskSleepers were rotated between huts using a Latin square design.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were not randomized to huts, but instead were rotated fully between all of the huts using a Latin square design.Treatment rotationLow riskTreatments were rotated between huts using a Latin square designStandardized hut designLow riskHuts were built in a standard West‐African design.Hut cleaning between treatmentsLow riskAll huts were cleaned between treatments.Were incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reported.Trial authors\' conflicting interestLow riskFunders of the trial stated that they had no part in data collection, data analysis or manuscript preparation[Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}MethodsCluster‐randomized controlled village trialParticipants3966 children analysed (21 months after intervention) aged 6 months‐14 years (excluding the severely ill)*, Anopheles* species (pooled). Total core cluster population area ranged from 14,845 to 16,358.InterventionsControl: LLIN, Olyset Net\
Intervention: LLIN, Olyset PlusOutcomesMalaria infection prevalence, sporozoite rate, mosquito densityMosquito resistance statusResistance ‐ high (17.8% mortality, N = 107)Net treatmentNets unholed and unwashedLocation(s)Muleba District, TanzaniaNotesTrial conducted: March 2014‐December 2016***Risk of bias*BiasAuthors\' judgementSupport for judgement**Recruitment biasLow riskNo participants recruited after clusters had been randomizedWere the mosquitoes in LLIN and LLIN + PBO groups comparableUnclear riskResistance level was only available for the whole district, not at village level.Collectors blindedLow riskField workers were masked to net treatment.Household blindedLow riskInhabitants were masked to net treatmentTreatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskRestricted randomization was used to allocate clusters to the study groups.Allocation concealment (selection bias)Low riskRestricted randomization was used to allocate treatments to clustersWere incomplete outcome data adequately addressedLow riskNo incomplete outcome dataWere the raw data reported for LLIN and LLIN + PBO groupsLow riskNo missing outcome dataClusters lost to follow‐upLow riskNo clusters lost to follow‐upSelective reporting (reporting bias)Low riskAll measured outcomes appear to be reportedCorrect statistical methods; adjusted for clusteringLow riskClustering was taken into account and adjusted for during statistical analysisTrial authors\' conflicting interestLow riskThe trial authors declared no conflicting interests.[Stiles‐Ocran 2013](#CD012776-bbs2-0013){ref-type="ref-list"}MethodsVillage trialParticipants*An gambiae*InterventionsControl: LLIN, PermaNet 2.0\
Intervention: LLIN, PermaNet 3.0OutcomesSporozoite rate, mosquito density, parity rateMosquito resistance statusFuta ‐ resistant ‐ moderate (33.3% mortality, N = 96)  Abrabra‐ resistant ‐ moderate (43.7% mortality, N = 126)  Kunkumso ‐ resistant ‐ high (28.4% mortality, N = 109)  Anyinabrim ‐ resistant ‐ moderate (53.2% mortality, N = 109)  Wenchi ‐ resistant ‐ low (61.9% mortality, N =126)Net treatmentNets unholed and unwashedLocation(s)Futa, Ghana ‐ no net control  Abrabra, Ghana ‐ PermaNet 2.0  Kunkumso, Ghana ‐ PermaNet 2.0  Anyinabrim, Ghana ‐ PermaNet 3.0  Wench, Ghana ‐ PermaNet 3.0NotesTrial conducted: November 2010‐August 2011***Risk of bias*BiasAuthors\' judgementSupport for judgement**Recruitment biasLow riskRecruiment bias is related to human participants and so not applicable to this study.Were the mosquitoes in LLIN and LLIN + PBO groups comparableUnclear riskMosquito species composition varied slightly. Resistance level varies between villages. Data are, however, provided pre‐ and post‐trial.Collectors blindedHigh riskNot stated if collectors were blinded, therefore judged as high risk as this is likely to affect searching effort.Household blindedLow riskUnclear if households were blinded -- not stated in the publication. We judged this as low as this is unlikely to impact on the outcome.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskVillages were randomly assigned to treatment arms.Allocation concealment (selection bias)Low riskAllocation concealment procedures were not adhered to, however this is unlikely to affect the results.Were incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reported.Clusters lost to follow‐upLow riskNo clusters lost to follow‐upSelective reporting (reporting bias)Low riskAll measured outcomes appear to be reported.Correct statistical methods; adjusted for clusteringHigh riskStudy did not take clustering into account for statistical methodsTrial authors\' conflicting interestUnclear riskStudy data were collected for use in Vestergaard PermaNet 3.0 product dossier[Toé 2018](#CD012776-bbs2-0014){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An coluzzii*InterventionsControl: LLIN, PermaNet 2.0, Olyset Net\
Intervention: LLIN, PermaNet 3.0, Olyset PlusOutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito resistance statusVallée du Kou 5 ‐ resistant -- high (deltamethrin, 2.5% mortality, N = 163; permethrin, 5% mortality, N = 153)\
Tengrela ‐ resistant -- high (deltamethrin, 34% mortality, N = 85; permethrin, 14% mortality, N = 101)Net treatmentNets holed, nets unwashedLocation(s)Vallée du Kou 5, Burkina Faso\
Tengrela, Burkina FasoNotesTrial conducted: September 2014‐October 2014***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskHuts situated in the same area -- mosquito characteristics will be the sameCollectors blindedUnclear riskUnclear if collectors blinded -- not stated in publicationSleepers blindedUnclear riskUnclear if sleeper blinded -- not stated in publicationSleeper biasLow riskSleepers were rotated between huts using a Latin square design.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were not randomized to huts, but instead were rotated fully between all of the huts using a Latin square design.Treatment rotationLow riskTreatments were rotated between huts using a Latin square design.Standardized hut designLow riskHuts were built in a standard West‐African design.Hut cleaning between treatmentsUnclear riskUnclear if huts were cleaned between treatments -- not stated in the publicationWere incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reported.Trial authors\' conflicting interestLow riskThe trial authors have no competing interests.[Tungu 2010](#CD012776-bbs2-0015){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An gambiae*InterventionsControl: LLIN, PermaNet 2.0\
Intervention: LLIN, PermaNet 3.0OutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito resistance statusSusceptible (deltamethrin, 100% mortality, N = not stated)Net treatmentNets holed, nets unwashed and washed (x 20)Location(s)Zeneti, Muheza, TanzaniaNotesTrial conducted: July 2008‐October 2008***Risk of bias*BiasAuthors\' judgementSupport for judgement**Were the mosquitoes in LLIN and LLIN + PBO groups comparableLow riskHuts situated in the same area -- mosquito characteristics will be the sameCollectors blindedUnclear riskUnclear if collectors blinded -- not stated in publicationSleepers blindedUnclear riskUnclear if sleeper blinded -- not stated in publicationSleeper biasLow riskSleepers were rotated between huts using a Latin square design.Treatment allocation (was the treatment allocation sequence randomly/adequately generatedLow riskTreatments were randomly allocated to huts.Treatment rotationLow riskTreatments were rotated between huts using a Latin square design.Standardized hut designLow riskHuts were built in a standard West‐African design.Hut cleaning between treatmentsLow riskAll huts were cleaned between treatmentsWere incomplete outcome data adequately addressedLow riskThere were no incomplete data.Were the raw data reported for LLIN and LLIN + PBO groupsLow riskAll necessary data were reported.Trial authors\' conflicting interestLow riskThe trial authors have no competing interests.[^1]

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD012776-sec2-0025}
======================================================================

[Koudou 2012](#CD012776-bbs2-0016){ref-type="ref-list"}MethodsVillage trialParticipantsBouaké ‐ 100% *An gambiae*: (70% S‐form, 30% M‐form)  Tiassalé ‐ 100% *An gambiae*: (70% S‐form, 30% M‐form)InterventionsControl: LLIN, PermaNet 2.0 Extra,\
Intervention: LLIN, PermaNet 3.0OutcomesBlood feeding, mosquito densityMosquito Resistance StatusBouaké ‐ resistant ‐ moderate (43.9% mortality, N = 114)  Tiassalé ‐ resistant ‐ moderate (7.5% mortality, N = 106)Net TreatmentNets unholed and unwashedLocation(s)Bouaké, Côte d'Ivoire  Tiassalé, Côte d'IvoireNotesTrial conducted: November 2009‐January 2012[Martine 2017](#CD012776-bbs2-0017){ref-type="ref-list"}MethodsCluster‐randomized controlled village trialParticipantsWild mosquitoes in Muleba, Tanzania (*An gambiae* and *An funestus*)InterventionsControl: LLIN, Olyset Net\
Intervention: LLIN, Olyset PlusOutcomesPhysical integrity of the net\
Number of mosquitoes resting inside net\
Insecticidal activityMosquito Resistance StatusAt baseline using adopted WHO resistance assays, field mosquitoes were 7%, 13% and 60%, 63% (*An gambiae*, *An funestus*) resistant to Olyset Plus and standard Olyset nets.Net TreatmentNets unholed and unwashedLocation(s)TanzaniaNotesEntomological trial that was part of [Protopopoff 2018](#CD012776-bbs2-0012){ref-type="ref-list"}[N'Guessan 2016](#CD012776-bbs2-0018){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An gambiae*InterventionsControl: LLIN, MAGNet LN\
Intervention: LLIN, Veeralin LNOutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito Resistance Status Net TreatmentNets holed, nets unwashed and washed (x 20)Location(s)M'be, Côte d'IvoireNotes [Shono 2017](#CD012776-bbs2-0019){ref-type="ref-list"}MethodsNot availableParticipantsNot availableInterventionsNot availableOutcomesNot availableMosquito Resistance StatusNot availableNet TreatmentControl: LLIN, Olyset Net\
Intervention: LLIN, Olyset PlusLocation(s)Not availableNotes [Tungu 2017](#CD012776-bbs2-0020){ref-type="ref-list"}MethodsExperimental hut trialParticipants*An funestus*InterventionsControl: LLIN, DawaPlus 2.0\
Intervention: LLIN, DawaPlus 3.0, DawaPlus 4.0OutcomesMosquito mortality, blood feeding, deterrence, exophilyMosquito Resistance Status Net TreatmentNets holed, nets unwashed and washed (x 20)Location(s)Muheza, TanzaniaNotes [^2]

Characteristics of ongoing studies \[ordered by study ID\] {#CD012776-sec2-0026}
==========================================================

[ISRCTN17516395](#CD012776-bbs2-0021){ref-type="ref-list"}Trial name or titleImpact of long‐lasting insecticide treated bed nets with and without piperonly butoxide (PBO) on malaria indictators in UgandaMethodsCluster‐randomized trialParticipantsHouseholds with at least one adult resident and one child aged 2‐10 years.InterventionsPermaNet 2.0\
PermaNet 3.0\
Olyset Net\
Olyset PlusOutcomesPrimary outcomes; parasite prevalence (proportion of thick blood smears that are positive for asexual parasites) in children ages 2‐10 years, asssessed prior to net distribution, and up to 3 times after nets are distributed.\
Secondary outcomes; prevalence of anaemia and mean haemoglobin in children ages 2‐10 years, frequency of molecular markers associated with insecticide resistance in the primary malaria vector, prevalence of phenotypic insecticide resistance in mosquitoes.Starting dateJanuary 2017Contact informationProfessor Martin DonnellyNotes [NCT03289663](#CD012776-bbs2-0022){ref-type="ref-list"}Trial name or titleEffectiveness study of new generation bednets in the context of conventional insecticide resistance in the Democratic Republic of the Congo (Net‐PBO)MethodsCluster‐randomized trialParticipants1680 participants, 0‐10‐year‐old subjects in 30 villagesInterventionsControl: bed net treated with pyrethroid only\
Intervention: bed net treated with both pyrethroid and PBOOutcomesIncidence rate of laboratory confirmed clinical cases of Malaria (time frame: participants will be actively followed up for 12 months and any suspected case of clinical malaria will immediately lead to microscopy and RDT for confirmation.) Microscopy to confirm the diagnosis of malaria sporozoite rate (time frame: *Anopheles* mosquitoes will be captured every 3 months during 1 year), sporozoite detection by ELISA to determine infectivity of *Anopheles*Starting date2 October 2017Contact information Notes [^3]

Previously PBO‐nets were classified as PBO‐LLINs, however as the durability of PBO on nets has not been classified as long lasting, these were subsequently referred to as pyrethroid‐PBO nets. As a result of this our review title changed from 'Piperonyl butoxide (PBO) combined with pyrethroids in long‐lasting insecticidal nets (LLINs) to prevent malaria in Africa\' to 'Piperonyl butoxide (PBO) combined with pyrethroids in insecticide‐treated nets (ITNs) to prevent malaria in Africa\'.

We added Leslie Choi as a review author.

Additional criteria for assessing the risk of bias of village trials were added. These are in line with the Cochrane 'Risk of bias' tool ([Higgins 2017](#CD012776-bbs2-0035){ref-type="ref-list"}), and the five additional criteria listed in Section 16.3.2 of the *Cochrane Handbook for Systematic Reviews of Interventions* that relate specifically to cluster‐randomized trials ([Higgins 2011](#CD012776-bbs2-0034){ref-type="ref-list"}).

The published protocol stated all stratified analysis factors under subgroup analysis ([Gleave 2017](#CD012776-bbs2-0067){ref-type="ref-list"}). We have corrected this to state that subgroup analysis was only performed on whether nets were unwashed or washed.

KG, NL, and HR conceived and designed the protocol.

KG and NL conducted the trial screening, data extraction and analysis.

MR and LC provided statistical support.

KG, NL, and HR wrote the final manuscripts, and all review authors approved the final manuscript.

HR is the guarantor of the review.
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Department for International Development, UK.Project number 300342‐104World Health Organization (WHO), Switzerland.WHO Global Malaria Programme Agreement for Performance of Work (APW) Grant 2017 (number 709319)
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[^1]: Abbreviations: *An arabiensis*:*Anopheles arabiensis*;*An coluzzii*:*Anopheles coluzzii*;*An funestus: Anopheles funestus*;*An gambiae*: *Anopheles gambiae*; ITN: insecticide‐treated net; LLIN: long‐lasting insecticidal net(s); PBO: piperonyl butoxide

[^2]: Abbreviations: *An funestus: Anopheles funestus*;*An gambiae*: *Anopheles gambiae*; LLIN: long‐lasting insecticidal net(s)

[^3]: Abbreviations: ELISA: enzyme‐linked immunosorbent assay; PBO: piperonyl butoxide
